Innoveren Scientific (IVRN) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 12, 2019
Document And Entity Information
Entity Registrant Name	H-CYTE, INC.
Entity Central Index Key	0001591165
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		98,886,413
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash	$ 300,068	$ 69,628
Accounts receivable	13,896	15,242
Other receivables	65,865	5,144
Inventory	129,264
Prepaid expenses	294,585	59,678
Total Current Assets	803,678	149,692
Right-of-use asset	973,386
Property and equipment, net	259,209	266,916
Intangibles, net	3,312,000
Goodwill	11,348,724
Other assets	29,239	38,288
Total Assets	16,726,236	454,896
Current Liabilities
Interest payable	149,861	158,371
Accounts payable	717,079	851,604
Accounts payable to related parties		180,000
Accrued liabilities	422,458	183,183
Other current liabilities	733,111	462,856
Notes payable	193,445	30,852
Short-term note payable, net of debt discount	625,982
Dividend payable	97,315
Deferred revenue	838,377	326,064
Lease liability, current portion	482,632
Total Current Liabilities	4,260,260	2,192,930
Long-Term Liabilities
Lease liability, net of current portion	511,930
Convertible debt to related parties		4,306,300
Deferred rent		22,206
Total Long-Term Liabilities	511,930	4,328,506
Total Liabilities	4,772,190	6,521,436
Commitments and Contingencies (Note 10)
Stockholders' Equity (Deficit)
Preferred Stock, value
Common stock - $.001 par value: 199,000,000 and 49,500,000 shares authorized as of June 30, 2019 and December 31, 2018, respectively. 98,886,360 and 33,661,388 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	98,887	33,661
Additional paid-in capital	25,705,975	3,566,339
Accumulated deficit	(13,480,691)	(9,296,408)
Non-controlling interest	(370,132)	(370,132)
Total Stockholders' Equity (Deficit)	11,954,046	(6,066,540)
Total Liabilities and Stockholders' Equity (Deficit)	16,726,236	454,896
Series A Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, value
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, value	7
Series C Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit)
Preferred Stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	199,000,000	49,500,000
Common stock, shares issued	98,886,360	33,661,388
Common stock, shares outstanding	98,886,360	33,661,388
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	7,000	0
Preferred stock, shares outstanding	7,000	0
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	45,000	45,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues	$ 2,431,721	$ 2,441,007	$ 3,755,961	$ 5,343,804
Cost of Sales	(492,145)	(644,236)	(988,964)	(1,475,373)
Gross Profit	1,939,576	1,796,771	2,766,997	3,868,431
Operating Expenses
Salaries and related costs	3,480,354	888,643	5,164,686	2,178,034
Other general and administrative	1,885,133	784,905	3,283,810	1,673,670
Advertising	1,584,850	419,337	2,720,396	1,156,842
Depreciation & amortization	208,619	24,391	419,837	48,888
Total Operating Expenses	7,158,956	2,117,276	11,588,729	5,057,434
Operating Loss	(5,219,380)	(320,505)	(8,821,732)	(1,189,003)
Other Income (Expense)
Other income			2,152
Foreign currency transaction gain	9,194		6,837
Interest expense	(87,085)	(42,217)	(179,344)	(70,919)
Total Other Expenses	(77,891)	(42,217)	(170,355)	(70,919)
Net Loss	(5,297,271)	(362,722)	(8,992,087)	(1,259,922)
Dividend on outstanding Series B Preferred Stock	21,000		45,639
Deemed dividend on adjustment to exercise price on certain warrant			404,384
Deemed dividend on beneficial conversion features			32,592
Net loss attributable to common stockholders	$ (5,318,271)	$ (362,722)	$ (9,474,702)	$ (1,259,922)
Loss per share – Basic and Diluted	$ (0.06)	$ (0.01)	$ (0.11)	$ (0.04)
Weighted average outstanding shares used to compute basic and diluted net loss per share	96,407,668	33,661,388	87,236,222	33,661,388

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Beginning Balance at Dec. 31, 2018		$ 33,661	$ 3,566,339	$ (9,296,408)	$ (370,132)	$ (6,066,540)
Beginning Balance, Shares at Dec. 31, 2018		33,661,388
Purchase Accounting entries due to the purchase transaction (note 3)	$ 9	$ 24,717	12,657,182			12,681,908
Purchase Accounting entries due to the purchase transaction, shares	9,250	24,717,217
Adjustment for assets and liabilities not included in purchase transaction				5,244,780		5,244,780
Issuance of common stock in connection with private placement offering from January 8, 2019 through June 30, 2019		$ 17,500	4,324,923			4,342,423
Issuance of common stock in connection with private placement offering from January 8, 2019 through June 30, 2019, shares		17,500,000
Issuance of warrants in connection with private placement offering from January 8, 2019 through June 30, 2019			2,641,161			2,641,161
Issuance of common stock pursuant to conversion of short-term debt in January 2019		$ 500	125,437			125,937
Issuance of common stock pursuant to conversion of short-term debt in January 2019, shares		500,000
Issuance of warrants pursuant to conversion of short-term debt in January 2019			74,063			74,063
Issuance of additional exchange shares - Note 3		$ 17,264	(17,264)
Issuance of additional exchange shares - Note 3, shares		17,263,889
Issuance of common stock pursuant to conversion of short-term debt in February 2019		$ 250	99,750			100,000
Issuance of common stock pursuant to conversion of short-term debt in February 2019, shares		250,000
Issuance of common stock pursuant to conversion of convertible Preferred Series B Stock conversions	$ (2)	$ 513	(511)
Issuance of common stock pursuant to conversion of convertible Preferred Series B Stock conversions, shares	(2,050)	512,500
Issuance of common stock pursuant to conversion of short-term debt accrued interest		$ 2	665			667
Issuance of common stock pursuant to conversion of short-term debt accrued interest, shares		1,667
Issuance of common stock pursuant to conversion of convertible Preferred Series B Stock accrued interest		$ 32	12,894			12,926
Issuance of common stock pursuant to conversion of convertible Preferred Series B Stock accrued interest, shares		32,313
Issuance of common stock in March 2019 in exchange for consulting fees incurred in Q1 2019		$ 130	51,904			52,034
Issuance of common stock in March 2019 in exchange for consulting fees incurred in Q1 2019, shares		130,085
Issuance of common stock in private placement, completed in April 2019 at $0.40 pursuant to security purchase agreement dated March 31, 2019
Issuance of warrants in private placement, completed in April 2019 at $0.40 pursuant to security purchase agreement dated March 31, 2019
Adjustment of exercise price of certain warrants			404,384	(404,384)
Beneficial conversion of preferred series B stock			32,592	(32,592)
Issuance of common stock pursuant to conversion of Preferred Series B Stock conversions		$ 50	(50)
Issuance of common stock pursuant to conversion of Preferred Series B Stock conversions, shares	(200)	50,000
Issuance of common stock pursuant to conversion of Preferred Series B Stock accrued dividends		$ 42	(42)
Issuance of common stock pursuant to conversion of Preferred Series B Stock accrued dividends, shares		41,667
Issuance of common stock per restricted stock award to executive (Note 9)		$ 4,226	1,686,028			1,690,254
Issuance of common stock per restricted stock award to executive (Note 9), shares		4,225,634
Stock based compensation			92,159			92,159
Dividend payable			(45,639)			(45,639)
Net loss				(8,992,087)		(8,992,087)
Ending Balance at Jun. 30, 2019	$ 7	$ 98,887	25,705,975	(13,480,691)	(370,132)	11,954,046
Ending Balance, shares at Jun. 30, 2019	7,000	98,886,360
Beginning Balance at Mar. 31, 2019	$ 7	$ 94,037	17,610,529	(8,183,420)	(370,132)	9,151,021
Beginning Balance, Shares at Mar. 31, 2019	7,200	94,036,746
Purchase Accounting entries due to the purchase transaction (note 3)			6,215,000			6,215,000
Purchase Accounting entries due to the purchase transaction, shares
Issuance of common stock in connection with private placement offering from January 8, 2019 through June 30, 2019		$ 500	123,977			124,477
Issuance of common stock in connection with private placement offering from January 8, 2019 through June 30, 2019, shares		500,000
Issuance of warrants in connection with private placement offering from January 8, 2019 through June 30, 2019			75,523			75,523
Issuance of common stock pursuant to conversion of convertible Preferred Series B Stock accrued interest		32	12,893			12,926
Issuance of common stock pursuant to conversion of convertible Preferred Series B Stock accrued interest, shares		32,313
Issuance of common stock pursuant to conversion of Preferred Series B Stock conversions		$ 50	(50)
Issuance of common stock pursuant to conversion of Preferred Series B Stock conversions, shares	(200)	50,000
Series B Stock accrued dividends		$ 42	(42)
Series B Stock accrued dividends, shares		41,667
Issuance of restricted common stock pursuant to executive employment agreement		$ 4,226	1,686,028			1,690,254
Issuance of restricted common stock pursuant to executive employment agreement, shares		4,225,634
Stock based compensation			3,116			3,116
Dividend payable			(21,000)			(21,000)
Net loss				(5,297,271)		(5,297,271)
Ending Balance at Jun. 30, 2019	$ 7	$ 98,887	$ 25,705,975	$ (13,480,691)	$ (370,132)	$ 11,954,046
Ending Balance, shares at Jun. 30, 2019	7,000	98,886,360

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Equity (Deficit) (Parenthetical)	Jun. 30, 2019$ / shares
Statement of Stockholders' Equity [Abstract]
Issuance of common stock in private placement price per share	$ 0.40
Issuance of warrants in private placement price per share	$ 0.40

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows from Operating Activities
Net loss	$ (8,992,087)	$ (1,259,922)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	419,837	48,888
Amortization of debt discount	127,863
Stock-based compensation	1,782,413
Common stock issued for consulting services	52,034
Changes in operating assets and liabilities, net of purchase transaction:
Accounts receivable	147,103	(19,169)
Other receivables	(60,722)
Accounts receivable from related parties		47,033
Inventory	2,191
Prepaid expenses and other assets	(41,665)	73,422
Interest payable	4,838	49,574
Accounts payable	(691,635)	26,283
Accounts payable to related parties	(180,000)
Accrued liabilities	(222,779)	(116,412)
Other current liabilities	555,056	133,232
Dividend payable	(6,137)
Deferred revenue	512,313	(567,063)
Net Cash Used in Operating Activities	(6,591,377)	(1,584,134)
Cash Flows from Investing Activities
Purchases of property and equipment	(13,703)	(203,695)
Purchase of business, net of cash acquired	(302,710)
Net assets not included in purchase transaction	(69,629)
Net Cash Used in Investing Activities	(386,042)	(203,695)
Cash Flows from Financing Activities
Payments on notes payable obligations	(84,381)	(2,424)
Borrowings from notes payable obligations	8,656	8,081
Proceeds from issuance of preferred and common stock, net of offering costs	4,417,946
Proceeds from issuance of warrants, net of offering costs	2,565,638
Proceeds from issuance of note payable		1,967,724
Proceeds from contribution from stockholders	300,000
Net Cash Provided by Financing Activities	7,207,859	1,973,381
Net Increase in Cash	230,440	185,552
Cash - Beginning of period	69,628	251,330
Cash - End of period	300,068	436,882
Supplementary Cash Flow Information
Cash paid for interest	3,700	20,900
Non-cash investing and financing activities
Financing agreement for insurance policy	139,715
Conversion of note and accrued interest to common stock and warrants	100,667
Issuance of common stock for Series B Preferred Stock conversion	605
Dividends accrued	$ 45,639

Description of the Company

Description of the Company	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Description of the Company	Note 1 - Description of the Company On July 11, 2019, Medovex Corp. (“MedoveX”) changed its named to “H-CYTE, Inc.” (H-CYTE or the Company) by filing a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of the State of Nevada. The name change and the Company’s new symbol, HCYT, became effective with FINRA on July 15, 2019. On October 18, 2018, H-CYTE (formerly named MedoveX) entered into an Asset Purchase Agreement with Regenerative Medicine Solutions, LLC, RMS Shareholder, LLC (“Shareholder”), Lung Institute LLC (“LI”), RMS Lung Institute Management LLC (“RMS LI Management”) and Cognitive Health Institute Tampa, LLC (“CHIT”), (collectively “RMS”). On January 8, 2019, the Asset Purchase Agreement was amended and the Company acquired certain assets and assumed certain liabilities of RMS as reported in the 8-K/A filed in March of 2019. Based on the terms of the Asset Purchase Agreement and its amendment, the former RMS members had voting control of the combined company as of the closing of the RMS acquisition. For accounting purposes, the acquisition transaction has been treated as a reverse acquisition whereby the Company is deemed to have been acquired by RMS and the historical financial statements prior to the acquisition date of January 8, 2019 now reflect the historical financial statements of RMS. Prior to the merger of H-CYTE and RMS on January 8, 2019, the consolidated results for H-CYTE included the financial activities of Regenerative Medicine Solutions, LLC, LI, RMS Nashville, LLC (“Nashville”), RMS Pittsburgh, LLC (“Pittsburgh”), RMS Scottsdale, LLC (“Scottsdale”), RMS Dallas, LLC (“Dallas”), State, LLC (“State”), CHIT, RMS LI Management, and Shareholder, H-CYTE included Lung Institute Dallas, PLLC (“LI Dallas”), Lung Institute Nashville, PLLC (“LI Nashville”), Lung Institute Pittsburgh, PLLC (“LI Pittsburgh”), and Lung Institute Scottsdale, LLC (“LI Scottsdale”), as VIEs. As of the merger, the consolidated results for H-CYTE include the following wholly-owned subsidiaries: Debride Inc., Blue Zone Health Management, LLC (“BZHM”, changed in July to H-CYTE Management, LLC), Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC (formerly Blue Zone Lung Tampa, LLC). Additionally, H-CYTE has consolidated LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale, as VIEs. The Company’s RMS division is a healthcare medical biosciences company that develops and implements advanced innovative treatment options in regenerative medicine to treat an array of debilitating medical conditions. In addition, the company is the operator and manager of the various Lung Health Institute clinics. Committed to an individualized patient-centric approach, RMS consistently provides oversight and management of the highest quality care while producing positive outcomes. RMS offices are located in Tampa, Florida. The Lung Health Institute located in Tampa, Florida is a wholly owned subsidiary of RMS. RMS also provides oversight and management to the Lung Health Institutes located in Nashville, TN, Scottsdale AZ, Pittsburgh, PA, and Dallas, TX. The Company is also in the business of designing and marketing proprietary medical devices for commercial use in the United States and Europe. The Company received CE marking in June 2017 for the DenerveX System and it is now commercially available throughout the European Union and several other countries that accept CE marking. The Company’s first sale of the DenerveX System occurred in July 2017. The Company plans to seek approval for the DenerveX System from the Food & Drug Administration (“FDA”) in the United States. The Company is presently reevaluating its approaches to revenue generation including the continuing use of its distribution channels and source of manufacturing.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2 – Basis of presentation and Summary of Significant Accounting Policies Based on the terms of the Asset Purchase Agreement and its amendment, the former RMS members had voting control of the combined company as of the closing of the RMS acquisition. RMS is deemed to be the acquiring company for accounting purposes and the transaction is accounted for as a reverse acquisition under the acquisition method of accounting for business combinations in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The assets acquired and the liabilities assumed of RMS included as part of the purchase transaction are recorded at historical cost. Accordingly, the assets and liabilities of H-CYTE are recorded as of the merger closing date at their estimated fair values. (See Note 3.) Further, the Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Stockholders’ Equity (Deficit), and the Consolidated Statements of Cash Flows do not reflect the historical financial information related to H-CYTE prior to the merger. The Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Stockholders’ Equity (Deficit), and the Consolidated Statements of Cash Flows only reflect the historical financial information related to RMS prior to the merger. For the Consolidated Statements of Stockholders’ Equity (Deficit), the common stock, preferred stock, and additional paid in capital reflect the accounting for the stock received by the RMS members as of the merger as if it was received as of the beginning of the periods presented. The Consolidated Statements of Stockholders’ Equity (Deficit) reflects the activity from March 31, 2019 to June 30, 2019 and December 31, 2018 to June 30, 2019. For the comparable period from December 31, 2017 to June 30, 2018, the only activity in the Consolidated Statement of Stockholders’ Equity (Deficit) were the losses of approximately $362,722 and $1,259,922 for the three and six months ended June 30, 2018, respectively. The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. GAAP and with the rules and regulations of the Securities and Exchange Commission (“SEC”) that permit reduced disclosure for interim periods. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments which included only normal recurring adjustments, necessary to present fairly the Company’s financial position as of June 30, 2019 and December 31, 2018 and the results of operations and cash flows for the three and six months ended June 30, 2019 and 2018. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements, and notes thereto for the fiscal year ended December 31, 2018, included in the Company’s Annual Report on Form 10-K. The December 31, 2018 financial information included in the Company’s Annual Report on Form 10-K reflect the historical financial information of H-CYTE business and do not include the RMS financial information. With the reverse merger, historical financial information for periods prior to the merger on January 8, 2019, presented in the comparative financial information included in the 2019 Form 10-Q, will only reflect the historical financial information related to RMS prior to the merger. (See Note 3.) The results for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other interim period or for any future year. Principles of Consolidation U.S. GAAP requires that a related entity be consolidated with a company when certain conditions exist. An entity is considered to be a variable interest entity (VIE) when it has equity investors who lack the characteristics of having a controlling financial interest, or its capital is insufficient to permit it to finance its activities without additional subordinated financial support. Consolidation of a VIE by the Parent would be required if it is determined that the Parent will absorb a majority of the VIE’s expected losses or residual returns if they occur, retain the power to direct or control the VIE’s activities, or both. Prior to the merger of H-CYTE and RMS on January 8, 2019, the consolidated results for H-CYTE include the financial activities of Regenerative Medicine Solutions, LLC, LI, Nashville, Pittsburgh, Scottsdale, Dallas, State, CHIT, RMS LI Management, and Shareholder. Additionally, H-CYTE has consolidated LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale, as VIEs. As of the merger, the consolidated results for H-CYTE include the following wholly-owned subsidiaries: Debride Inc., Blue Zone Health Management, LLC (“BZHM”, changed in July to H-CYTE Management, LLC), Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC (formerly Blue Zone Lung Tampa, LLC). Additionally, H-CYTE has consolidated LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale, as VIEs. The accompanying consolidated financial statements include the accounts of the parent, its wholly-owned subsidiaries, and its VIEs. Accounts Receivable Accounts receivable primarily represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. Trade accounts receivable are stated net of an estimate made for doubtful accounts, if any. Management evaluates the adequacy of the allowance for doubtful accounts regularly to determine if any account balances will potentially be uncollectible. Customer account balances are considered past due or delinquent based on the contractual agreement with each customer. Accounts are written off when, in management’s judgment, they are considered uncollectible. At June 30, 2019 and December 31, 2018, management believes no allowance is necessary. For the three month period ended June 30, 2019, we recorded bad debt expense of approximately $60,000. Goodwill And Intangibles Goodwill is recorded at fair value and not amortized but is reviewed for impairment at least annually or more frequently if impairment indicators arise. Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value is “more likely than not” less than the carrying amount or if significant changes related to the business have occurred that could materially impact fair value, a quantitative goodwill impairment test would be required. The Company can elect to forego the qualitative assessment and perform the quantitative test. If the carrying amount exceeds its fair value, “Step 1” is performed to determine if goodwill is impaired and to measure the amount of impairment loss to recognize, if any. This step compares the implied fair value of goodwill with the carrying amount of goodwill. If the carrying amount of goodwill exceeds the implied fair value, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined by assigning the fair value to all the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination. The Company has elected to perform the annual impairment assessment for goodwill in the fourth quarter. Intangibles acquired in a business combination are recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Intangible assets with definite lives are amortized over the estimated useful lives and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may be greater than fair value. The Company’s intangible assets are patents and related proprietary technology for the DenerveX System. Leases In February 2016, the Financial Accounting Standard Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2019-01, Codification Improvements; ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company has not entered into significant lease agreements in which it is the lessor; however, the Company does have lease agreements in which it is the lessee. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the lease commencement date. Effective January 1, 2019, the Company adopted this guidance, applied the modified retrospective transition method and elected the transition option to use the effective date as the date of initial application. The Company recognized the cumulative effect of the transition adjustment on the consolidated balance sheet as of the effective date and did not provide any new lease disclosures for periods before the effective date. With respect to the practical expedients, the Company elected the package of transitional-related practical expedients and the practical expedient not to separate lease and non-lease components. At January 1, 2019, additional current lease liabilities of $475,000 and long-term lease liabilities of $713,000 with corresponding ROU assets of $1,167,000 were recognized based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. Other Receivables Other receivables totaling approximately $66,000 at June 30, 2019 include receivables from the non-acquired Lung Institute, LLC to Lung Institute Tampa, LLC (formerly Blue Zone Lung Tampa) for approximately $53,000, approximately $9,000 reimbursement receivable for reimbursement of expenses from a joint study with an unrelated third party and approximately $4,000 reimbursement receivable from the non-acquired Regenerative Medicine Solutions, LLC and affiliates. The $53,000 receivable was a result of Lung Institute, LLC being a transitory entity for Lung Institute Tampa, LLC while general liability insurance and the merchant services accounts were being transferred. A portion of the $53,000 receivable totaling $20,000 was paid to Lung Institute Tampa, LLC in July 2019. Revenue Recognition The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the FASB Accounting Standards Codification 606, Revenue From Contracts with Customers, which requires that five steps be completed to determine when revenue can be recognized: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. The Company records revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. The adoption of this standard did not have a material impact on the consolidated financial statements. DenerveX System The Company sells the DenerveX System through a combination of direct sales and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company only records revenue when collectability is reasonably assured. Utilizing the five-step method outlined in Topic 606 to determine when revenue should be recognized, the Company’s policy is to recognize revenue when product is shipped to the customer, whether that customer is a distributor or an end user, as is the case in Germany. Biomedical Services RMS wholly owns the Tampa, Florida Lung Health Institute (LHI) location and manages the other Lung Health Institute locations. The Lung Health Institute uses a standard pricing model for the types of cellular therapy treatments that is offered to its patients. The transaction price accounts for medical, surgical, facility, and office services rendered by LHI for consented procedures and is recorded as revenue. The company recognizes revenue when the terms of a contract with a patient are satisfied. LHI offers two types of cellular therapy treatments to their patients. The first type of treatment includes medical services rendered typically over a two-day period in which the patient receives cellular therapy. For this treatment type, revenue is recognized in full at time of service. LHI also offers a four-day treatment in which medical services are rendered typically over a two-day period and then again, approximately three months later, medical services are rendered for an additional two-days of treatment. Payment is collected in full for both service periods at the time the first treatment is rendered. Revenue is recognized when services are performed based on the related professional, facility, and diagnostic services for each session of treatment. The Company has deferred recognition of revenue amounting to approximately $838,000 and $326,000 at June 30, 2019 and December 31, 2018, respectively. Advertising The Company expenses all advertising costs as incurred. For the three and six months ended June 30, 2019, the Company had approximately $1,585,000 and $2,720,000, respectively, in advertising costs, as compared to $419,000 and $1,157,000, respectively, for the three and six months ended June 30, 2018. Use of Estimates In preparing the financial statements, U.S. GAAP requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. The Company’s significant estimates include deferred revenue, the deferred income tax asset and the related valuation allowance, and the fair value of its share-based payment arrangements. For those estimates that are sensitive to the outcome of future events, actual results could differ from those estimates. Foreign Currency Transactions The Company transacts some of its operating activities in foreign currencies, most notably the Euro. The Company also has certain assets and liabilities denominated in foreign currencies that are translated to U.S. Dollars for reporting purposes as of and for the three and six months ended June 30, 2019. These amounts are immaterial and are included in other income (expense) for the three and six months ended June 30, 2019. Because of the immaterial effect noted above, the Company did not present a separate statement of other comprehensive income. Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation I ncome From inception to June 30, 2019, the Company has incurred net losses and, therefore, has no current income tax liability. The net deferred tax asset generated by these losses is fully reserved as of June 30, 2019 and December 31, 2018, respectively, since it is currently likely that the benefit will not be realized in future periods. As a result of the acquisition, the Company is required to file federal income tax returns and state income tax returns in the states of Arizona, Florida, Georgia, Minnesota, Pennsylvania, Tennessee, and Texas. There are no uncertain tax positions at June 30, 2019 or December 31, 2018. The Company has not undergone any tax examinations since inception. Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses. For the periods presented, there is no difference between the basic and diluted net loss per share: 30,108,743 warrants and 517,509 common stock options outstanding were considered anti-dilutive and excluded for the period ended June 30, 2019. For the six-month period ended June 30, 2018, there were no dilutive securities as the accounting acquirer did not historically have stock compensation programs.

Business Acquisition

Business Acquisition	6 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
Business Acquisition	Note 3 – Business Acquisition On January 8, 2019, H-CYTE completed its business combination with RMS under which H-CYTE purchased certain assets and assumed certain liabilities of RMS. Pursuant to the terms of the Asset Purchase Agreement, H-CYTE issued to the shareholders of RMS 33,661 shares plus 6,111 additional exchange shares (based on closing the sale of $2 million of new securities) for a total of 39,772 shares of Series C Preferred Stock where each share of Series C Preferred stock will, at the date of closing, automatically convert into 1,000 shares of Common Stock and represent approximately fifty-five percent (55%) of the outstanding voting shares of the Company. Under the terms of the Asset Purchase Agreement, subsequent to the closing, the Company issued additional “Exchange Shares” to the shareholders of RMS to maintain the 55% ownership and not be diluted by the sale of convertible securities (“New Shares Sold”) until H-CYTE raised an additional $5.65 million via the issuance of new securities. On the date of closing the Company issued 6,111 additional Exchange Shares to RMS Shareholders as a result of the issuance of additional securities, which are included in the 39,772 shares above. Subsequent to the closing of the purchase transaction all additional Exchange Shares have been issued to the shareholders of RMS for a total of 17,264 additional Series C Preferred Stock which automatically converted to 1,000 shares of Common Stock. Because RMS shareholders own approximately 55% of the voting stock of H-CYTE after the transaction, RMS is deemed to be the acquiring company for accounting purposes (the “Acquirer”) and the transaction is accounted for as a reverse acquisition under the acquisition method of accounting for business combinations in accordance with U.S. GAAP. The assets acquired and the liabilities assumed of RMS included as part of the purchase transaction are recorded at historical cost. Accordingly, the assets and liabilities of H-CYTE (the “Acquiree”) are recorded as of the merger closing date at their estimated fair values. Under the terms of the business combination with RMS, H-CYTE purchased certain assets and assumed certain liabilities of RMS. The assets of RMS reported on the H-CYTE consolidated balance sheet as of December 31, 2018 that were excluded in the January 8, 2019 transaction were cash of approximately $70,000. The liabilities of RMS reflected on the H-CYTE consolidated balance sheet as of December 31, 2018 but not assumed in the transaction included the following: convertible debt to a related party of approximately $4.3 million, interest payable of approximately $158,000, accounts payable of approximately $224,000 and other current liabilities of approximately $285,000. Additionally, there were certain on-going litigation matters that were not assumed as part of the January 8, 2019 RMS reverse acquisition. Purchase Price Allocation The purchase price for the acquisition of the Acquiree has been allocated to the assets acquired and liabilities assumed based on their estimated fair values. The purchase price allocation herein is preliminary. The final purchase price allocation will be determined after completion of a thorough analysis to determine the fair value of all assets acquired and liabilities assumed but in no event later than one year following completion of the acquisition. Accordingly, the final acquisition accounting adjustments could differ materially from the allocation reflected as of June 30, 2019 presented herein. Any increase or decrease in the fair value of the assets acquired and liabilities assumed, as compared to the information shown herein, could also materially change the portion of purchase price allocated to goodwill and could materially impact the operating results of the Company following the acquisition due to differences in purchase price allocation, depreciation and amortization related to some of these assets and liabilities. During the three months ended June 30, 2019 the Company revised its purchase price allocation for the acquisition. As a result, the Company recorded a measurement period adjustment of $6,215,000 as an increase to goodwill adjusting the amount recorded as of March 31, 2019. The adjustment resulted in corresponding increase of $6,215,000 to additional paid in capital. The acquisition-date fair value of the consideration transferred is as follows: Common shares issued and outstanding 24,717,271 Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock 2,312,500 Total Common shares 27,029,771 Closing price per share of MDVX Common stock on January 8, 2019 $ 0.40 10,811,908 Fair value of outstanding warrants and options 2,220,000 Cash consideration to RMS (350,000 ) Total consideration $ 12,681,908 Just prior to the transaction, H-CYTE had 24.5 million shares of common stock outstanding at a market capitalization of $9.8 million. The estimated fair value of the net assets of H-CYTE was $8.4 million as of January 8, 2019. Measuring the fair value of the net assets to be received by RMS was readily determinable based upon the underlying nature of the net assets. The fair value of the H-CYTE common stock is above the fair value of its net assets. The H-CYTE net asset value is primarily comprised of definite-lived intangibles as of the closing and the RMS interest in the merger is significantly related to obtaining access to the public market. Therefore, the fair value of the H-CYTE stock price and market capitalization as of the closing date is considered to be the best indicator of the fair value and, therefore, the estimated purchase price consideration. The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition on January 8, 2019: Cash $ (302,710 ) Accounts receivable, net 145,757 Inventory 131,455 Prepaid expenses 46,153 Property and equipment 30,393 Other 2,751 Intangibles 3,680,000 Goodwill 11,348,724 Total assets acquired $ 15,082,523 Accounts payable and other accrued liabilities 1,645,399 Interest-bearing liabilities and other 755,216 Net assets acquired $ 12,681,908 Intangible assets are recorded as definite-lived assets and amortized over the estimated period of economic benefit. Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. Goodwill is not expected to be deductible for income tax purposes. Goodwill is recorded as an indefinite-lived asset and is not amortized but tested for impairment on an annual basis or when indications of impairment exist. Total interest bearing and other liabilities assumed are as follows: Notes payable $ 99,017 Convertible notes payable 598,119 Dividend payable 57,813 Deferred rent 267 Total interest-bearing and other liabilities $ 755,216 Notes payable relate to promissory notes assumed by Aquiree in a 2015 acquisition, which was later divested in 2016, with the assumed promissory notes being retained by Aquiree. Payments on both of the notes are due in aggregate monthly installments of approximately $5,700 and carry an interest rate of 5%. Both of the notes have a maturity date of August 1, 2019. The Company is in the process of finalizing an eighteen month extension on the notes. The promissory notes had outstanding balances of approximately $99,000 plus accrued interest of approximately $3,000 at January 8, 2019. (See Note 11.) Convertible notes were issued pursuant to a securities purchase agreement with select accredited investors, whereby the Acquiree offered up to 1,000,000 in units at a purchase price of $50,000 per unit. Each Unit consisted of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants are exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. As a result of the price adjustment feature, the conversion price of the convertible notes was adjusted to $0.36 per share. The convertible notes have maturity dates between August and September 2019. The Company is in the process of negotiating a 30-day extension of the maturity dates. The notes are secured by all of the assets of the Company. (See Note 11.) ASU 2017-11, Earnings Per Share (Topic 260), provided that when determining whether certain financial instruments should be classified as liability or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. If a down round feature on the conversion option embedded in the note is triggered, the Company will evaluate whether a beneficial conversion feature exists, and if one is determined to exist the Company will record the amount as a debt discount and will amortize it over the remaining term of the debt. The down round feature embedded in the conversion option was triggered on January 8, 2019, as such, the Company recognized the down round as a deemed dividend of approximately $437,000 which reduced the income available to common stockholders. In the offering, the Acquiree sold an aggregate of 15 units and issued to investors an aggregate of $750,000 in principal amount of convertible notes and 1,875,000 warrants to purchase common stock, resulting in total gross proceeds of $750,000 to the Company. If converted at $0.40 the convertible notes sold in the offering are convertible into an aggregate of 1,875,000 shares of common stock. The Acquiree recorded the proceeds from the notes and the accompanying warrants, which accrete over the period the notes are outstanding, on a relative fair value basis of approximately $505,000 and $245,000, respectively. At acquisition date, the value of the notes was approximately $598,000. The following schedule represents the amounts of revenue and net loss attributable to the MedoveX acquisition which have been included in the consolidated statements of operations for the periods subsequent to the acquisition date: Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 Revenues $ - $ 35,505 Net loss attributable to H-CYTE (894,585 ) (1,948,962 ) The following unaudited pro forma financial information represents the consolidated financial information as if the acquisition had been included in the consolidated results beginning on the first day of the fiscal year prior to its acquisition date. The pro forma results have been calculated after adjusting the results of the acquired entity to remove any intercompany transactions and transaction costs incurred and to reflect any additional depreciation and amortization that would have been charged assuming the fair value adjustments to property and equipment and intangible assets had been applied on the first day of the fiscal year prior to its acquisition date, together with the consequential tax effects. The pro forma results do not reflect any cost savings, operating synergies or revenue enhancements that the combined may achieve as a result of the acquisition; the costs to combine the companies’ operations; or the costs necessary to achieve these cost savings, operating synergies or revenue enhancements. The pro forma results do not necessarily reflect the actual results of operations of the combined companies’ under the current ownership and operation. For the Three Months Ending June 30, 2018 RMS MedoveX Pro Forma Revenues $ 2,441,007 $ 249,425 $ 2,690,432 Net loss (362,722 ) (1,085,900 ) $ (1,448,622 ) Net loss attributable to common shareholders (362,722 ) (1,352,957 ) $ (1,715,679 ) Loss per share- basic and diluted $ (0.01 ) $ (0.03 ) For the Six Months Ending June 30, 2018 RMS MedoveX Pro Forma Revenues $ 5,343,804 $ 392,614 $ 5,736,418 Net loss (1,259,922 ) (2,339,686 ) $ (3,599,608 ) Net loss attributable to common shareholders (1,259,922 ) (2,606,743 ) $ (3,866,665 ) Loss per share- basic and diluted $ (0.01 ) $ (0.07 )

Inventory

Inventory	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventory	Note 4 - Inventory Inventory consists only of finished goods and is valued at the lower of cost or net realizable value, using the first-in, first-out (FIFO) method. Inventories were acquired in the merger transaction from the H-CYTE business and therefore there were no inventories prior to January 8, 2019. Inventory consisted of the following: June 30, 2019 December 31, 2018 DenerveX device $ 3,014 $ — Pro-40 generator 126,250 — Total $ 129,264 $ —

Right-of-use Asset and Lease Li

Right-of-use Asset and Lease Liability	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Right-of-use Asset and Lease Liability	Note 5 – Right-of-use Asset And Lease Liability In February 2016, the FASB established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The Company implemented the new standard effective January 1, 2019. On adoption, additional current liabilities of approximately $475,000 and long-term liabilities of approximately $713,000 with corresponding ROU assets of approximately $1,167,000 were recognized, based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases. The consolidated balance sheet at June 30, 2019 reflects current lease liabilities of approximately $483,000 and long-term liabilities of $512,000, with corresponding ROU assets of $973,000. The Company leases corporate office space in Tampa, FL and Atlanta, GA. The Company also leases medical clinic space in Tampa, FL, Nashville, TN, Scottsdale, AZ, Pittsburgh, PA, and Dallas, TX. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. As of June 30, 2019, maturities of lease liabilities are as follows: Remainder of 2019 $ 240,000 2020 454,000 2021 139,000 2022 94,000 2023 68,000 $ 995,000

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 6 - Property and Equipment Property and equipment, net, consists of the following: Useful Life June 30, 2019 December 31, 2018 Furniture and fixtures 5-7 years $ 214,272 $ 149,285 Computers and software 3-7 years 292,510 278,234 Leasehold improvements 15 years 156,279 156,133 663,061 583,652 Less accumulated depreciation (403,852 ) (316,736 ) Total $ 259,209 $ 266,916 Depreciation expense amounted to approximately $25,000 and $52,000, respectively, for the three and six months ended June 30, 2019. Depreciation expense amounted to approximately $25,000 and $49,000 respectively, for the three and six months ended June 30, 2018 .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note 7 - Goodwill And Intangible Assets Goodwill The Company performs a goodwill impairment analysis at least annually (in the fourth quarter of each year) unless indicators of impairment exist in interim periods. The assumptions used in the analysis are based on the Company’s internal budget. The Company projected revenue, operating margins and cash flows for a period of five years, and applied a perpetual long-term growth rate thereafter. These assumptions are reviewed annually as part of management’s budgeting and strategic planning cycles. These estimates may differ from actual results. The values assigned to each of the key assumptions reflect management’s past experience as their assessment of future trends, and are consistent with external/internal sources of information. As of June 30, 2019, no indicators of impairment existed. Intangible Assets The following table presents the changes in intangible assets during the period: Balance at December 31, 2018 $ — Acquisition during the period 3,680,000 Balance at June 30, 2019 3,680,000 Amortization during the six months ended June 30, 2019 (368,000 ) Intangible assets, net $ 3,312,000 The following is a schedule of expected future amortization of intangible assets as of June 30, 2019: Amount Remainder of 2019 $ 368 ,000 2020 736,000 2021 736,000 2022 736,000 2023 736,000 Total $ 3,312,000

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 – Related Party Transactions Consulting Expense As described in Note 10, the Company entered into an oral consulting agreement with Mr. Raymond Monteleone, Board Member and Chairman of the Audit Committee, in which Mr. Monteleone receives $10,000 per month for advisory services and $5,000 per quarter as Audit Committee Chair. This arrangement has no specified termination date. For the three and six months ended June 30, 2019, the Company has expensed $35,000 and $70,000 in compensation to Mr. Monteleone, respectively. Board Member Expenses For the three and six months ended June 30, 2019, the Company paid $5,000 each for Board of Director fees to Michael Yurkowsky and to Raymond Monteleone for a total of $10,000 and $10,000 respectively. Debt Obligations The Company had various related party transactions in 2018. For the period of January 1, 2018 to March 13, 2018, the Company received $528,175 from one of its shareholders (RMS members) and $228,175 from its CEO (RMS CEO) as part of a line of credit that was established in 2017. The entire line of credit between the Member and the CEO in the amount of $1,856,350, including contributions from 2017, was transferred to the BioCell Capital, LLC debt instrument on March 13, 2018. The BioCell Capital Line of Credit also consisted of related parties which contributed approximately $4,300,000, inclusive of the aforementioned $1,856,300, to the Company in 2018. The Company also received a short-term note from one of its shareholders (RMS members), who was also the CEO of H-CYTE, in the amount of $180,000 in December 2018 for working capital needs.

Equity Transactions

Equity Transactions	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Equity Transactions	Note 9 - Equity Transactions For the Consolidated Statements of Stockholders’ Equity (Deficit) as of December 31, 2018, the common stock, preferred stock and additional paid in capital reflect the accounting for the stock received by the RMS members as of the merger as if it was received as of the beginning of the periods presented and the historical accumulated deficit of RMS. As of the acquisition closing, before the contingent additional exchange shares impact from the sale of new securities, the stock received by RMS was 33,661 shares of Series C Preferred Stock, converted into approximately 33,661,000 shares of common stock, with common stock par value of approximately $33,700 and additional paid-in capital of approximately $3,566,000. The historical accumulated deficit of RMS as of the closing was approximately $9,296,000. Common Stock Issuance On January 8, 2019, the Company entered into a securities purchase agreement (the “SPA”) with four purchasers (the “Purchasers”) pursuant to which the four Purchasers invested in the Company an aggregate amount of $2,000,000, with $1,800,000 in cash and $200,000 by cancellation of debt as explained below, in exchange for forty (40) units (the “Units”), each consisting of a convertible note (the “Convertible Note”) with the principal amount of $50,000 and a warrant (the “Warrant”) to purchase common stock (the “Common Stock”) of the Company. Pursuant to this SPA, the Company initially offered a minimum of $1,000,000 and a maximum of $6,000,000, and subsequently increased to a maximum of $8,000,000 (the “Maximum Amount”) of Units at a price of $50,000 per Unit until the earlier of i) the closing of the subscription of the Maximum Amount and ii) March 31, 2019 (the “Termination Date”), subject to the Company’s earlier termination at its discretion. The SPA includes the customary representations and warranties from the Company and purchasers. Steve Gorlin, the Company’s former Chairman of the Board, converted a $200,000 promissory note owed to him by the Company in exchange for four (4) Units on the same terms as all other Purchasers. The promissory note was converted into an aggregate of 500,000 shares of common stock, eliminating the Company’s debt obligation. Each Convertible Note offered by the Company as part of the Unit bears an interest rate of 12% per annum, had a principal amount of $50,000, shall mature in one year from the original issue date on January 8, 2019, and will be convertible into shares of Common Stock at a price of $0.40 subject to adjustment stated in the Convertible Note. Pursuant to the terms of the Convertible Note, each holder of the Convertible Notes shall not own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Common Stock issuable upon exercise of such Convertible Note. If defaulted, the penalty interest rate of the Convertible Note shall rise to 18% per annum. In addition, pursuant to the SPA, the Company offers, as part of the Unit, Warrants to purchase the Common Stock at a price of $0.75 per share (the “Exercise Price”), subject to adjustments stated therein. The holder of each Warrant may purchase the number of shares of Common Stock equal to the number of shares of Common Stock issuable upon conversion of each Convertible Note while the Warrant is exercisable. The Warrants have a term of three years and shall be exercised in cash or on a cashless basis as described in the Warrant. All of such notes have been converted into an aggregate of 18,000,000 shares of common stock. As reported on Form 8-K filings on January 25, 2019, February 8, 2019, March 15, 2019 and April 5, 2019, the Company entered into other SPA’s with additional purchasers, which brought the aggregate amount of capital raised in all these offerings to $7,200,000, as of that latest date. As a result of the sales of new securities of at least $5.65 million, total additional Exchange shares of approximately 17,264 Series C Preferred Stock were issued and automatically converted to 17,263,889 shares of Common Stock. All the Convertible Notes from the SPA as well as the shares of Series C Preferred Stock issued to RMS members were automatically converted into shares of Common Stock. The foregoing description of the SPA, Convertible Note, and Warrant is qualified in its entirety by reference to the respective agreements. In February 2019, 250,000 shares of common stock were issued pursuant to conversion of short-term debt and accrued interest. In March 2019, the Company issued an aggregate of 130,085 shares of common stock at $0.40 per share shares for consulting fees in an amount equivalent to $52,034. On April 25, 2019, the Company issued 4,225,634 shares of common stock valued at $.40 per share to Mr. William Horne, the Company’s CEO, in a restricted stock award which was 100% vested when issued. This restricted stock award was issued pursuant to his employment agreement with the Company, which stated that this restricted stock award (as well as the incentive stock options issued in the quarter ended March 31, 2019) would be fully vested if not issued within fifteen days of the RMS merger transaction. Neither award was issued within that time frame and both awards became fully vested when issued. The aggregate number of shares of common stock from these two awards is 4,475,634 and was calculated based on 7% of the Company’s issued and outstanding common stock as of the closing of the RMS merger. The Company recognized approximately $1,690,000 of compensation expense in the quarter ended June 30, 2019 related to the restricted stock award. This expense should have been recognized in the quarter ended March 31, 2019. Though the quantitative impact is material, the Company believes the qualitative aspects of this misstatement should be the primary driver in determining whether or not this misstatement is material. The Company believes this misstatement to be immaterial to the quarter ended March 31, 2019 and June 30, 2019 financial statements from a qualitative impact evaluation. During the six months ended June 30, 2019, 636,480 shares were issued pursuant to convertible Preferred Series B Stock and accrued dividends conversion. Series B Preferred Stock Preferences Voting Rights Preferred Series B Stockholders have the right to receive notice of any meeting of holders of Common Stock or Series B Preferred Stock and to vote upon any matter submitted to a vote of the holders of Common Stock or Series B Preferred Stock. Each holder of Series B Preferred Stock shall vote on each matter submitted to them with the holders of Common Stock. Liquidation Upon the liquidation, dissolution or winding up of the business of the Company, whether voluntary or involuntary, each holder of Series B Preferred Stock shall be entitled to receive, for each share thereof, out of assets of the Company legally available therefor, a preferential amount in cash equal to the stated value plus all accrued and unpaid dividends. All preferential amounts to be paid to the holders of Series B Preferred Stock in connection with such liquidation, dissolution or winding up shall be paid before the payment or setting apart for payment of any amount for, or the distribution of any assets of the Company’s to the holders of the Company’s Common Stock. The Company accrues these dividends as they are earned each period. On January 8, 2019, the Company completed the issuance of convertible debt in the SPA transaction with a conversion price of $0.40. As a result, accordingly the exercise price on all of the warrants issued with the Series B Shares were adjusted downward to 90% of that conversion price or $0.36. In conjunction with the downward adjustment, the Company recorded a deemed dividend of approximately $117,000 representing the difference in the fair value of the warrants immediately before and after the adjustment to the exercise price. The Company recognized a beneficial conversion feature related to the Series B Shares of approximately $33,000, which was credited to additional paid-in capital, and reduced the income available to common shareholders. Because the Series B Shares can immediately be converted by the holder, the beneficial conversion feature was immediately accreted and recognized as a deemed dividend to the preferred shareholders. Series B preferred Stock Conversions During the six months ended June 30, 2019, 9,250 Series B Preferred Stock with a par value of $.001 were assumed with the merger transaction and an aggregate of 2,250 shares of Series B Preferred Stock, and accrued dividends, were subsequently converted into an aggregate of 562,500 shares of authorized common stock, par value $0.001 per share. Debt Conversion Convertible Notes The $750,000 convertible notes payable assumed in the acquisition transaction, had a fair value of approximately $598,000 on the acquisition date. Subsequently, on February 6, 2019, $100,000 of the outstanding convertible notes was converted into an aggregate of 250,000 shares of common stock, eliminating $100,000 of the Company’s debt obligation. The debt was converted into shares at $0.40 per share, which was the conversion price per the SPA. In connection with the Asset Purchase Agreement (“APA”) and APA Amendment, on January 8, 2019, Steve Gorlin, the Company’s former Chairman of the Board, converted a $200,000 promissory note owed to him by the Company pursuant to the same terms of the SPA entered into by other investors to consummate the acquisition on January 8, 2019. The promissory note was converted into an aggregate of 500,000 shares of common stock, eliminating the Company’s debt obligation. Stock-Based Compensation Plan 2013 Stock Option Incentive Plan The Company utilizes the Black-Scholes valuation method to recognize stock-based compensation expense over the vesting period. The expected life represents the period that the stock-based compensation awards are expected to be outstanding. For the three and six months ended June 30, 2019, the Company recognized approximately $3,000 and $92,000 as compensation expense with respect to vested stock options. No compensation expense was recorded prior to the RMS reverse merger transaction. Since these stock options were assumed on January 8, 2019 as part of the RMS reverse merger transaction, there were no historical costs related to this prior to January 8, 2019. The expense for the six months ended June 30, 2019 is related to an option for 250,000 shares that were awarded to the Company’s CEO that were 100% vested and were issued pursuant to his employment agreement. This option was granted pursuant to his employment agreement with the Company, which stated that this option grant would be fully vested if not issued within fifteen days of the RMS reverse merger transaction. The option was not granted within that time frame and was fully vested when issued. Including the expense of approximately $1,690,000 related to the restricted stock award to the Company’s CEO, total stock-based compensation expense for the three and six months ended June 30, 2019 were approximately $1,693,000 and $1,782,000, respectively. The three and six months ended June 30 include $1,690,254 related to the Company’s CEO restricted stock award which was 100% vested when issued. This restricted stock award was issued pursuant to his employment agreement with the Company, which stated that this option grant would be fully vested if not issued within fifteen days of the RMS reverse merger transaction. The restricted stock award was not issued within that time frame and was fully vested when issued. Stock Option Activity As of June 30, 2019, there were 9,502 shares of unvested stock options. Unrecognized compensation cost amounted to approximately $3,900 as of June 30, 2019 and will be recognized as an expense on a straight-line basis over a remaining weighted average service period of 1 year. The following is a summary of stock option activity for the six months ending June 30, 2019: Shares Weighted Weighted Outstanding at December 31, 2018 — $ — — Assumed with the RMS merger transaction 557,282 $ 2.78 6.99 Other activity since January 8, 2019: Granted 250,000 $ 0.40 9.53 Cancelled (289,774 ) $ 2.59 — Outstanding at June 30, 2019 517,508 $ 1.81 7.87 Exercisable at June 30, 2019 508,006 $ 1.81 7.87

Commitments & Contingencies

Commitments & Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 10 – Commitments & Contingencies Biotechnology Agreement The Company, on June 21, 2019, entered into a 10-year exclusive and extendable product supply agreement with Rion LLC (“Rion”) that will enhance its existing cytotherapy product line, developing a disruptive technology for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a unique exosome technology to harness the healing power of the body. Rion’s novel exosome technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular and neurological organ systems. With this agreement, Rion will serve as the product supplier and will co-develop a proprietary cellular platform with H-CYTE for the treatment of COPD. H-CYTE will control the commercial development and facilitate clinical trial investigation. After conducting joint research and development of these biologics, H-CYTE intends to pursue submission of an investigational new drug (IND) application for review by the U.S. Food and Drug Administration (“FDA”) for treatment of COPD. Sublease Agreement The Company entered into a sub-lease agreement for the lease in Alpharetta, Georgia. The period of the lease is from July 1, 2019 to December 31, 2020 and sublessee shall pay to sublessor a minimum rent, of two thousand dollars ($2,000) per month. Consulting Agreements The Company has an agreement with Jesse Crowne, a former Director and Co-Chairman of the Board of the Company, to provide business development consulting services for a fee of $13,333 per month. The Company is in the process of negotiating a new contract with Mr. Crowne. The Company incurred expense of $0 and $39,999, for the three and six months ended June 30, 2019 related to this consulting agreement. Since this agreement was assumed January 8, 2019 as part of the RMS reverse merger transaction, there were no historical costs related to this prior to January 8, 2019. The Company entered into a consulting agreement with LilyCon Investments, LLC effective February 1, 2019 for services related to evaluation and negotiation of future acquisitions, joint ventures, and site evaluations/lease considerations. The contract duration is for a period of twelve (12) months in the amount of $12,500 per month with a $15,000 signing bonus which was paid in full during the quarter ending March 31, 2019. The agreement also provides LilyCon Investments with $35,000 in stock (calculated using an annual Variable Weighted Average Price from February 2019 through January 2020) to be granted on the one year anniversary of this agreement, if the agreement has not been terminated prior to that date. Either party may terminate this agreement with or without cause upon 30 days written notice. For the three and six months ended June 30, 2019, the Company has expensed a total of $37,500 and $77,500 in compensation to LilyCon Investments, respectively. The Company entered into an oral consulting agreement with Mr. Raymond Monteleone, Board Member and Chairman of the Audit Committee, in which Mr. Monteleone received $10,000 per month for advisory services and $5,000 per quarter as Audit Committee Chair. This arrangement has no specified termination date. For the three and six months ended June 30, 2019, the Company has expensed $35,000 and $70,000 in compensation to Mr. Monteleone, respectively. The Company entered into an oral consulting arrangement with St. Louis Family Office, LLC, controlled by Jimmy St. Louis, former CEO of RMS, in January 2019 in the amount of $10,000 per month plus benefits reimbursement for advisory services. The Company terminated this agreement effective June 30, 2019. For the three and six months ended June 30, 2019, the Company has expensed $44,000 and $71,000 in consulting fees to St. Louis Family Office, respectively. The Company entered into a consulting agreement with Strategos Public Affairs, LLC (Strategos) on February 15, 2019 for a period of twelve (12) months, unless otherwise terminated by giving thirty (30) days prior written notice. Strategos will provide information to key policymakers in the legislature and executive branches of government on the benefits of the cellular therapies offered by the Lung Health Institute, advocate for legislation that supports policies beneficial to patient access and oppose any legislation that negatively impacts the Company’s ability to expand treatment opportunities, and position the Company and its related entities as the expert for information and testimony. For the three and six months ended June 30, 2019, the Company has expensed $26,000 and $26,000 to Strategos Group for consulting services. Distribution center and logistic services agreement The Company has a non-exclusive distribution center agreement with a logistics service provider in Berlin, Germany pursuant to which they manage and coordinate the DenerveX System products which the Company exports to the EU through June 2019. The Company pays a fixed monthly fee of €4,500 (approximately $5,040) for all accounting, customs declarations and office support, and a variable monthly fee ranging from €1,900 to €6,900 (approximately $2,300 to $8,300), based off volume of shipments, for logistics, warehousing and customer support services. Total expenses incurred for the distribution center and logistics agreement were approximately $22,500 and $45,000, respectively, for the three and six months ended June 30, 2019. Since this agreement was assumed January 8, 2019 as part of the RMS reverse merger transaction, there were no historical costs related to this prior to January 8, 2019. Patent Assignment and Contribution Agreements The terms of a Contribution and Royalty Agreement dated January 31, 2013 with Dr. Scott Haufe, M.D was assumed in the merger transaction as of January 8, 2019. This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products. The royalty period expires on September 6, 2030. The Company incurred approximately $0 and $1,100, respectively, in royalty expense under the Contribution and Royalty agreement for the three months and six months ended June 30, 2019, all of which was included in accounts payable at June 30, 2019. Since this agreement was assumed January 8, 2019 as part of the RMS reverse merger transaction, there were no historical costs related to this prior to January 8, 2019. Litigation From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect the Company’s financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention and other factors. The Company expenses legal costs in the period incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against it in the future, and these matters could relate to prior, current or future transactions or events. Guarantee The Company has guaranteed payments based upon the terms found in the management services agreements to two affiliated physicians related to LI Nashville, LI Scottsdale, LI Pittsburgh, and LI Dallas. For the three and six months ending June 30, 2019, payments totaling approximately $34,000 and $56,000, respectively were made to these affiliates. For the three and six months ending June 30, 2018, payments totaling approximately $20,000 and $59,000, respectively were made to these affiliates.

Short Term Liabilities

Short Term Liabilities	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Short Term Liabilities	Note 11 - Short Term Liabilities Notes Payable Short-term notes payable relates to financing arrangements for Directors and Officers and general liability insurance premiums that were financed at various points throughout 2018 and first quarter 2019 and two promissory notes assumed in the merger transaction. These insurance financing arrangements require aggregate monthly payments of approximately $18,000 reflect interest rates ranging from 7% to 12.8% and are to be paid in full by April 2020 and had balances of approximately $95,000 at June 30, 2019 and $31,000 at December 31, 2018. Interest expense related to these insurance financing arrangements was approximately $2,000 and $2,300 for the three and six months ended June 30, 2019 and was $0 for the three and six months ended June 30, 2018 respectively. Both of the promissory notes payable assumed in the merger are due in aggregate monthly installments of approximately $5,700 and carry an interest rate of 5%. The Promissory Notes had outstanding balances of approximately $99,000 at date of merger transaction and approximately $99,000 at June 30, 2019. No scheduled payments have been made on these notes since the scheduled payment for January, 2018 except for a $5,700 payment made in June 2019. Both of the notes have a maturity date of August 1, 2019. The Company is in the process of finalizing an eighteen month extension on the notes. The Company incurred interest expense related to the promissory notes for the three and six months ended June 30, 2019 in the amount of approximately $1,300 and $2,100, respectively; no interest expense was incurred during 2018 as these notes were assumed on January 8, 2019. The Company’s interest expense of approximately $42,000 and $71,000 for the three and six months ended June 30, 2018 was related to convertible debt not assumed in the RMS acquisition as of January 8, 2019. Convertible Notes The Convertible notes payable represents a securities purchase agreement with select accredited investors, which were assumed in the merger transaction. The debt consisted of $750,000 in units at a purchase price of $50,000 per unit were assumed. Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants were initially exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. The notes are secured by all of the assets of the Company. The Company recorded the proceeds from the notes and the accompanying warrants, which accrete over the period the notes are outstanding, on a relative fair value basis of $505,424 and $244,576, respectively. Interest expense related to the discount on these convertible notes for the three and six month period ending June 30, 2019 was approximately $63,600 and $127,900, respectively. The Company recognized approximately $21,500 and $41,200, respectively, in unpaid accrued interest expense related to the notes for the three and six months ended June 30, 2019. The convertible notes sold in the offering were initially convertible into an aggregate of 1,875,000 shares of common stock. The down round feature was triggered on January 8, 2019, and the conversion price of the convertible debt were adjusted to $0.36. The Company recognized the down round as a deemed dividend of approximately $288,000 which reduced the income available to common stockholders. On February 6, 2019, $100,000 of the Company’s $750,000 outstanding convertible notes was converted into an aggregate of 277,778 shares of common stock, eliminating $100,000 of the Company’s debt obligation. The debt was converted into shares at $0.36 per share, which was the conversion price per the SPA subsequent to the trigger of the down round feature. The convertible notes have maturity dates between August and September 2019. The Company is in the process of negotiating a 30-day extension of the maturity dates. If the Company is unable to extend the maturity date, the notes will go into default until additional funding is received to payoff these notes and the mandatory default amounts will have to be paid. The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes.

Common Stock Warrants

Common Stock Warrants	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Common Stock Warrants	Note 12 - Common Stock Warrants Fair value measurement valuation techniques, to the extent possible, should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company’s fair value measurements of all warrants are designated as Level 1 since all of the significant inputs are observable and quoted prices used for volatility were available in an active market. A summary of the Company’s warrant issuance activity and related information for the six months ended June 30, 2019 is as follows: Shares Weighted Weighted Assumed as of the January 8, 2019 merger 12,108,743 $ 1.38 2.6 Issued 18,000,000 $ 0.75 2.59 Outstanding and exercisable at June 30, 2019 30,108,743 $ 0.95 (1)(2) 2.38 The fair value of all warrants issued are determined by using the Black-Scholes valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Black-Scholes valuation technique to value each of the warrants issued at June 30, 2019 as of their respective issue dates are as follows: Event Description Date H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 1/8/2019 $ 0.40 $ 0.75 $ 0.24 3 years 2.57 115.08 Private placement 1/18/2019 $ 0.40 $ 0.75 $ 0.23 3 years 2.60 114.07 Private placement 1/25/2019 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.72 Private placement 1/31/2019 $ 0.54 $ 0.75 $ 0.34 3 years 2.43 113.47 Private placement 2/7/2019 $ 0.57 $ 0.75 $ 0.36 3 years 2.46 113.23 Private placement 2/22/2019 $ 0.49 $ 0.75 $ 0.30 3 years 2.46 113.34 Private placement 3/1/2019 $ 0.52 $ 0.75 $ 0.33 3 years 2.54 113.42 Private placement 3/8/2019 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.53 Private placement 3/11/2019 $ 0.61 $ 0.75 $ 0.40 3 years 2.45 113.62 Private placement 3/26/2019 $ 0.51 $ 0.75 $ 0.32 3 years 2.18 113.12 Private placement 3/28/2019 $ 0.51 $ 0.75 $ 0.31 3 years 2.18 112.79 Private placement 3/29/2019 $ 0.51 $ 0.75 $ 0.31 3 years 2.21 112.79 Private placement 4/4/2019 $ 0.48 $ 0.75 $ 0.29 3 years 2.29 112.77 (1) (2) The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management's Plans	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management's Plans	Note 13 - Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $9,031,000 and $1,260,000 for the six months ended June 30, 2019 and 2018, respectively. The RMS products and services division will incur losses until sufficient revenue volume and geographical coverage is attained utilizing the infusion of capital resources to expand marketing and sales initiatives. In April 2019, the Company determined that their contract manufacturer was not able to meet the quality and quantity requirements for producing the DenerveX product. As a result, the manufacture of the DenerveX product has been temporarily suspended while the Company sources alternative manufacturing options. Additionally, in the Company’s review and evaluation of its current distribution channels, the Company has determined that many of these channels were not cost effective. As a result of the above evaluations, certain European distributor agreements were terminated, and all other representatives have been notified that the Company is temporarily suspending the manufacture and sale of the DenerveX product while the Company sources alternative manufacturing and distributor options as well as considers other product monetizing strategies. The MedoveX operations will continue to incur losses until the plan for the DenerveX System monetization is determined and executed. The Company’s independent registered public accounting firm has included an explanatory paragraph with respect to our ability to continue as a going concern in its report on the Company’s consolidated financial statements for the year ended December 31, 2018. The presence of the going concern explanatory paragraph suggests that the Company may not have sufficient liquidity or minimum cash levels to operate the business. Since our inception, the Company has incurred losses and anticipates that the Company will continue to incur losses until our products can generate enough revenue to offset our operating expenses. The Company through July 2019 has raised $7,100,000 (excluding $200,000 of debt conversions) year to date in additional cash to sustain the Company. Cash as of June 30, 2019 was approximately $300,000. The present level of cash is insufficient to satisfy our current operating requirements. On July 25 and July 26, 2019, the Company issued two promissory notes (the “Notes”) in the aggregate principal amount of $900,000 to Horne Management, LLC, and controlled by Mr. William E. Horne, the Chief Executive Officer of the Company. The Notes bear an interest rate of 5.5% per annum and are due on demand. The Company has received the funds represented by the Notes. The Company has certain convertible promissory notes in the aggregate principal amount of approximately $650,000 that mature in August and September 2019. The convertible notes are secured by all of the assets of the Company. The Company is currently negotiating a 30-day extension to the maturity date. If the Company is unable to extend the maturity date, the notes will go into default until additional funding is received to payoff these notes and the mandatory default amounts will have to be paid. The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes. The Company has certain promissory notes with outstanding balances of approximately $99,000 at June 30, 2019. The notes have a maturity date of August 1, 2019. The Company is in the process of finalizing an eighteen-month extension on the notes. The Company is pursuing raising additional funds from the sale of equity securities. On June 7, 2019 the Board of Directors approved a new private placements securities offering up to $8,500,000 of Common Stock at a price of $0.50 per share, and a three-year warrant to purchase such number of shares of Common Stock equal to fifty percent (50%) of the number of shares of Common Stock issuable as part of this Agreement (the “Warrants”), at an exercise price of $1.00 per share. The Company has raised $100,000 from these new private placement securities since June 30, 2019. There can be no assurances that the Company will be able to obtain additional financing on commercially reasonable terms, if at all. If the Company is required to curtail operations, there would be substantial doubt about the Company’s ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to the carrying value of amounts of its assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 14 - Subsequent Events On July 11, 2019, MedoveX changed its named to H-CYTE by filing the Amendment to the Company’s Certificate of Incorporation with the Secretary of the State of Nevada. The name change and the Company’s new symbol, HCYT became effective with FINRA on July 15, 2019. On July 25 and July 26, 2019, H-CYTE, Inc. (the “Company”) issued two promissory notes (the “Notes”) in the principal amount (the “Principal Amount”) of an aggregate of $900,000 to Horne Management, LLC, a limited liability located in Fort Lauderdale, Florida and controlled by Mr. William E. Horne, the Chief Executive Officer of the Company. The Notes bear an interest rate of 5.5% per annum and are due on demand. The Company has received the funds represented by the Notes. On July 29, 2019, the board of directors (the “Board”) of the Company appointed Dr. Andre Terzic to the Board. Dr. Andre Terzic, 57, has served as a director at the Center for Regenerative Medicine of Mayo Clinic in Rochester, Minnesota for the last five years. Dr. Andre Terzic is the Chair of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee of Food and Drug Administration, the President of the American Society for Clinical Pharmacology & Therapeutics, and one of the co-founders of Rion LLC. Rion is a Minnesota Bio-tech Company focused on cutting-edge regenerative technologies. Dr. Terzic received his M.D. at University of Belgrade in Paris, France in 1985 and his Ph.D. from the Department of Pharmacology of University of Illinois in 1991. On July 30, 2019, the Board appointed Dr. Atta Behfar as a member of the Board. Dr. Atta Behfar, 42, has worked as a cardiologist at the Department of Cardiovascular Medicine of Mayo Clinic for the last five years. Dr. Atta Behfar is a Director of the Van Cleve Cardiac Regenerative Medicine program at Mayo Clinic and one of the founders of Rion LLC. Dr. Behfar received a Bachelor of Science degree in Biochemistry from Marquette University in 1998 and a M.D. and Ph.D. from Mayo Clinic College of Medicine, Mayo Graduate School in 2006. The Company has certain convertible promissory notes in the aggregate principal amount of approximately $650,000 that mature between August 8, 2019 and September 28, 2019. The convertible notes are secured by all of the assets of the Company. The Company is currently negotiating a 30-day extension to the maturity date. If the Company is unable to extend the maturity date, the notes will go into default until additional funding is received to payoff these notes and the mandatory default amounts will have to be paid. The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes. The company has certain promissory notes with outstanding balances of approximately $99,000 at June 30, 2019. The notes have a maturity date of August 1, 2019. The Company is in the process of finalizing an eighteen-month extension on the notes.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation U.S. GAAP requires that a related entity be consolidated with a company when certain conditions exist. An entity is considered to be a variable interest entity (VIE) when it has equity investors who lack the characteristics of having a controlling financial interest, or its capital is insufficient to permit it to finance its activities without additional subordinated financial support. Consolidation of a VIE by the Parent would be required if it is determined that the Parent will absorb a majority of the VIE’s expected losses or residual returns if they occur, retain the power to direct or control the VIE’s activities, or both. Prior to the merger of H-CYTE and RMS on January 8, 2019, the consolidated results for H-CYTE include the financial activities of Regenerative Medicine Solutions, LLC, LI, Nashville, Pittsburgh, Scottsdale, Dallas, State, CHIT, RMS LI Management, and Shareholder. Additionally, H-CYTE has consolidated LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale, as VIEs. As of the merger, the consolidated results for H-CYTE include the following wholly-owned subsidiaries: Debride Inc., Blue Zone Health Management, LLC (“BZHM”, changed in July to H-CYTE Management, LLC), Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC (formerly Blue Zone Lung Tampa, LLC). Additionally, H-CYTE has consolidated LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale, as VIEs. The accompanying consolidated financial statements include the accounts of the parent, its wholly-owned subsidiaries, and its VIEs.
Accounts Receivable	Accounts Receivable Accounts receivable primarily represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. Trade accounts receivable are stated net of an estimate made for doubtful accounts, if any. Management evaluates the adequacy of the allowance for doubtful accounts regularly to determine if any account balances will potentially be uncollectible. Customer account balances are considered past due or delinquent based on the contractual agreement with each customer. Accounts are written off when, in management’s judgment, they are considered uncollectible. At June 30, 2019 and December 31, 2018, management believes no allowance is necessary. For the three month period ended June 30, 2019, we recorded bad debt expense of approximately $60,000.
Goodwill and Intangibles	Goodwill And Intangibles Goodwill is recorded at fair value and not amortized but is reviewed for impairment at least annually or more frequently if impairment indicators arise. Goodwill is evaluated for impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary. If it is determined, based on qualitative factors, that the fair value is “more likely than not” less than the carrying amount or if significant changes related to the business have occurred that could materially impact fair value, a quantitative goodwill impairment test would be required. The Company can elect to forego the qualitative assessment and perform the quantitative test. If the carrying amount exceeds its fair value, “Step 1” is performed to determine if goodwill is impaired and to measure the amount of impairment loss to recognize, if any. This step compares the implied fair value of goodwill with the carrying amount of goodwill. If the carrying amount of goodwill exceeds the implied fair value, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined by assigning the fair value to all the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination. The Company has elected to perform the annual impairment assessment for goodwill in the fourth quarter. Intangibles acquired in a business combination are recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Intangible assets with definite lives are amortized over the estimated useful lives and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may be greater than fair value. The Company’s intangible assets are patents and related proprietary technology for the DenerveX System.
Leases	Leases In February 2016, the Financial Accounting Standard Board (“FASB”) established Topic 842, Leases, by issuing Accounting Standards Update (ASU) No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2019-01, Codification Improvements; ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company has not entered into significant lease agreements in which it is the lessor; however, the Company does have lease agreements in which it is the lessee. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the lease commencement date. Effective January 1, 2019, the Company adopted this guidance, applied the modified retrospective transition method and elected the transition option to use the effective date as the date of initial application. The Company recognized the cumulative effect of the transition adjustment on the consolidated balance sheet as of the effective date and did not provide any new lease disclosures for periods before the effective date. With respect to the practical expedients, the Company elected the package of transitional-related practical expedients and the practical expedient not to separate lease and non-lease components. At January 1, 2019, additional current lease liabilities of $475,000 and long-term lease liabilities of $713,000 with corresponding ROU assets of $1,167,000 were recognized based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.
Other Receivables	Other Receivables Other receivables totaling approximately $66,000 at June 30, 2019 include receivables from the non-acquired Lung Institute, LLC to Lung Institute Tampa, LLC (formerly Blue Zone Lung Tampa) for approximately $53,000, approximately $9,000 reimbursement receivable for reimbursement of expenses from a joint study with an unrelated third party and approximately $4,000 reimbursement receivable from the non-acquired Regenerative Medicine Solutions, LLC and affiliates. The $53,000 receivable was a result of Lung Institute, LLC being a transitory entity for Lung Institute Tampa, LLC while general liability insurance and the merchant services accounts were being transferred. A portion of the $53,000 receivable totaling $20,000 was paid to Lung Institute Tampa, LLC in July 2019.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the FASB Accounting Standards Codification 606, Revenue From Contracts with Customers, which requires that five steps be completed to determine when revenue can be recognized: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. The Company records revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. The adoption of this standard did not have a material impact on the consolidated financial statements. DenerveX System The Company sells the DenerveX System through a combination of direct sales and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company only records revenue when collectability is reasonably assured. Utilizing the five-step method outlined in Topic 606 to determine when revenue should be recognized, the Company’s policy is to recognize revenue when product is shipped to the customer, whether that customer is a distributor or an end user, as is the case in Germany. Biomedical Services RMS wholly owns the Tampa, Florida Lung Health Institute (LHI) location and manages the other Lung Health Institute locations. The Lung Health Institute uses a standard pricing model for the types of cellular therapy treatments that is offered to its patients. The transaction price accounts for medical, surgical, facility, and office services rendered by LHI for consented procedures and is recorded as revenue. The company recognizes revenue when the terms of a contract with a patient are satisfied. LHI offers two types of cellular therapy treatments to their patients. The first type of treatment includes medical services rendered typically over a two-day period in which the patient receives cellular therapy. For this treatment type, revenue is recognized in full at time of service. LHI also offers a four-day treatment in which medical services are rendered typically over a two-day period and then again, approximately three months later, medical services are rendered for an additional two-days of treatment. Payment is collected in full for both service periods at the time the first treatment is rendered. Revenue is recognized when services are performed based on the related professional, facility, and diagnostic services for each session of treatment. The Company has deferred recognition of revenue amounting to approximately $838,000 and $326,000 at June 30, 2019 and December 31, 2018, respectively.
Advertising	Advertising The Company expenses all advertising costs as incurred. For the three and six months ended June 30, 2019, the Company had approximately $1,585,000 and $2,720,000, respectively, in advertising costs, as compared to $419,000 and $1,157,000, respectively, for the three and six months ended June 30, 2018.
Use of Estimates	Use of Estimates In preparing the financial statements, U.S. GAAP requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. The Company’s significant estimates include deferred revenue, the deferred income tax asset and the related valuation allowance, and the fair value of its share-based payment arrangements. For those estimates that are sensitive to the outcome of future events, actual results could differ from those estimates.
Foreign Currency Transactions	Foreign Currency Transactions The Company transacts some of its operating activities in foreign currencies, most notably the Euro. The Company also has certain assets and liabilities denominated in foreign currencies that are translated to U.S. Dollars for reporting purposes as of and for the three and six months ended June 30, 2019. These amounts are immaterial and are included in other income (expense) for the three and six months ended June 30, 2019. Because of the immaterial effect noted above, the Company did not present a separate statement of other comprehensive income.
Stock-Based Compensation	Stock-Based Compensation The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation
Income Taxes	I ncome From inception to June 30, 2019, the Company has incurred net losses and, therefore, has no current income tax liability. The net deferred tax asset generated by these losses is fully reserved as of June 30, 2019 and December 31, 2018, respectively, since it is currently likely that the benefit will not be realized in future periods. As a result of the acquisition, the Company is required to file federal income tax returns and state income tax returns in the states of Arizona, Florida, Georgia, Minnesota, Pennsylvania, Tennessee, and Texas. There are no uncertain tax positions at June 30, 2019 or December 31, 2018. The Company has not undergone any tax examinations since inception.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses. For the periods presented, there is no difference between the basic and diluted net loss per share: 30,108,743 warrants and 517,509 common stock options outstanding were considered anti-dilutive and excluded for the period ended June 30, 2019. For the six-month period ended June 30, 2018, there were no dilutive securities as the accounting acquirer did not historically have stock compensation programs.

Business Acquisition (Tables)

Business Acquisition (Tables)	6 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
Schedule of Fair Value of Consideration Transferred	The acquisition-date fair value of the consideration transferred is as follows: Common shares issued and outstanding 24,717,271 Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock 2,312,500 Total Common shares 27,029,771 Closing price per share of MDVX Common stock on January 8, 2019 $ 0.40 10,811,908 Fair value of outstanding warrants and options 2,220,000 Cash consideration to RMS (350,000 ) Total consideration $ 12,681,908
Schedule of Estimated Fair Values of the Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition on January 8, 2019: Cash $ (302,710 ) Accounts receivable, net 145,757 Inventory 131,455 Prepaid expenses 46,153 Property and equipment 30,393 Other 2,751 Intangibles 3,680,000 Goodwill 11,348,724 Total assets acquired $ 15,082,523 Accounts payable and other accrued liabilities 1,645,399 Interest-bearing liabilities and other 755,216 Net assets acquired $ 12,681,908
Schedule of Interest Bearing and Other Liabilities Assumed	Total interest- bearing and other liabilities assumed are as follows: Notes payable $ 99,017 Convertible notes payable 598,119 Dividend payable 57,813 Deferred rent 267 Total interest-bearing and other liabilities $ 755,216
Schedule of Revenue and Net Loss Attributable to Acquisition	The following schedule represents the amounts of revenue and net loss attributable to the MedoveX acquisition which have been included in the consolidated statements of operations for the periods subsequent to the acquisition date: Three Months Ended Six Months Ended June 30, 2019 June 30, 2019 Revenues $ - $ 35,505 Net loss attributable to H-CYTE (894,585 ) (1,948,962 )
Schedule of Pro Forma Financial Information	For the Three Months Ending June 30, 2018 RMS MedoveX Pro Forma Revenues $ 2,441,007 $ 249,425 $ 2,690,432 Net loss (362,722 ) (1,085,900 ) $ (1,448,622 ) Net loss attributable to common shareholders (362,722 ) (1,352,957 ) $ (1,715,679 ) Loss per share- basic and diluted $ (0.01 ) $ (0.03 ) For the Six Months Ending June 30, 2018 RMS MedoveX Pro Forma Revenues $ 5,343,804 $ 392,614 $ 5,736,418 Net loss (1,259,922 ) (2,339,686 ) $ (3,599,608 ) Net loss attributable to common shareholders (1,259,922 ) (2,606,743 ) $ (3,866,665 ) Loss per share- basic and diluted $ (0.01 ) $ (0.07 )

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following items as of June 30, 2019, and December 31, 2018: June 30, 2019 December 31, 2018 DenerveX device $ 3,014 $ — Pro-40 generator 126,250 — Total $ 129,264 $ —

Right-of-use Asset and Lease _2

Right-of-use Asset and Lease Liability (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Schedule of Maturities of Lease Liabilities	As of June 30, 2019, maturities of lease liabilities are as follows: Remainder of 2019 $ 240,000 2020 454,000 2021 139,000 2022 94,000 2023 68,000 $ 995,000

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net, consists of the following: Useful Life June 30, 2019 December 31, 2018 Furniture and fixtures 5-7 years $ 214,272 $ 149,285 Computers and software 3-7 years 292,510 278,234 Leasehold improvements 15 years 156,279 156,133 663,061 583,652 Less accumulated depreciation (403,852 ) (316,736 ) Total $ 259,209 $ 266,916

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The following table presents the changes in intangible assets during the period: Balance at December 31, 2018 $ — Acquisition during the period 3,680,000 Balance at June 30, 2019 3,680,000 Amortization during the six months ended June 30, 2019 (368,000 ) Intangible assets, net $ 3,312,000
Schedule of Future Amortization of Intangible Assets	The following is a schedule of expected future amortization of intangible assets as of June 30, 2019: Amount Remainder of 2019 $ 368 ,000 2020 736,000 2021 736,000 2022 736,000 2023 736,000 Total $ 3,312,000

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity for the six months ending June 30, 2019: Shares Weighted Weighted Outstanding at December 31, 2018 — $ — — Assumed with the RMS merger transaction 557,282 $ 2.78 6.99 Other activity since January 8, 2019: Granted 250,000 $ 0.40 9.53 Cancelled (289,774 ) $ 2.59 — Outstanding at June 30, 2019 517,508 $ 1.81 7.87 Exercisable at June 30, 2019 508,007 $ 1.81 7.87

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Summary of Warrant Activity	A summary of the Company’s warrant issuance activity and related information for the six months ended June 30, 2019 is as follows: Shares Weighted Weighted Assumed as of the January 8, 2019 merger 12,108,743 $ 1.38 2.6 Issued 18,000,000 $ 0.75 2.59 Outstanding and exercisable at June 30, 2019 30,108,743 $ 0.95 (1)(2) 2.38 (1) (2)
Schedule of Assumptions for Warrants	The inputs used in the Black-Scholes valuation technique to value each of the warrants issued at June 30, 2019 as of their respective issue dates are as follows: Event Description Date H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Private placement 1/8/2019 $ 0.40 $ 0.75 $ 0.24 3 years 2.57 115.08 Private placement 1/18/2019 $ 0.40 $ 0.75 $ 0.23 3 years 2.60 114.07 Private placement 1/25/2019 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.72 Private placement 1/31/2019 $ 0.54 $ 0.75 $ 0.34 3 years 2.43 113.47 Private placement 2/7/2019 $ 0.57 $ 0.75 $ 0.36 3 years 2.46 113.23 Private placement 2/22/2019 $ 0.49 $ 0.75 $ 0.30 3 years 2.46 113.34 Private placement 3/1/2019 $ 0.52 $ 0.75 $ 0.33 3 years 2.54 113.42 Private placement 3/8/2019 $ 0.59 $ 0.75 $ 0.38 3 years 2.43 113.53 Private placement 3/11/2019 $ 0.61 $ 0.75 $ 0.40 3 years 2.45 113.62 Private placement 3/26/2019 $ 0.51 $ 0.75 $ 0.32 3 years 2.18 113.12 Private placement 3/28/2019 $ 0.51 $ 0.75 $ 0.31 3 years 2.18 112.79 Private placement 3/29/2019 $ 0.51 $ 0.75 $ 0.31 3 years 2.21 112.79 Private placement 4/4/2019 $ 0.48 $ 0.75 $ 0.29 3 years 2.29 112.77

Description of the Company (Det

Description of the Company (Details Narrative)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
State of incorporation	NV

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 02, 2019	Dec. 31, 2018
Net Loss		$ 5,297,271	$ 362,722	$ 8,992,087	$ 1,259,922
Bad debt expenses			60,000
Current lease liabilities		482,632		482,632
Long-term lease liabilities		511,930		511,930
ROU assets		973,386		973,386
Other receivables		65,865		65,865			5,144
Deferred revenue recognition		838,377		838,377			$ 326,064
Advertising costs		1,584,850	$ 419,337	$ 2,720,396	$ 1,156,842
Anti-dilutive securities
Warrants [Member]
Anti-dilutive securities				30,108,743
Common Stock Options [Member]
Anti-dilutive securities				517,509
Lung Institute, LLC [Member]
Other receivables		53,000		$ 53,000
Reimbursement receivable		9,000		9,000
Regenerative Medicine Solutions, LLC [Member]
Reimbursement receivable		$ 4,000		$ 4,000
Lung Institute Tampa, LLC [Member] | Subsequent Event [Member]
Repayments to related party	$ 20,000
Accounting Standards Update (ASU) No. 2016-02 [Member]
Current lease liabilities						$ 475,000
Long-term lease liabilities						713,000
ROU assets						$ 1,167,000

Business Acquisition (Details N

Business Acquisition (Details Narrative) - USD ($)	Feb. 06, 2019	Jan. 08, 2019	Feb. 28, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Number of shares issued for acquisition, value				$ 6,215,000		$ 12,681,908
Number of shares converted	277,778
Percentage of voting interest acquired		55.00%
Proceeds from new issuance				124,477		4,342,423
Interest payable				149,861		149,861		$ 158,371
Accounts payable				717,079		717,079		851,604
Other current liabilities				$ 733,111		$ 733,111		$ 462,856
Increase in goodwill					$ 6,215,000
Increase in additional paid in capital		$ 6,215,000
Common stock, shares outstanding		24,500,000		98,886,360		98,886,360		33,661,388
Market capitalization		$ 9,800,000
Fair value of net assets		8,400,000
Common stock, par value				$ 0.001		$ 0.001		$ 0.001
Conversion price per share	$ 0.36
Debt converted into shares	250,000		250,000
Proceeds from notes							$ 1,967,724
Proceeds from warrants						2,565,638
Promissory Note [Member]
Aggregate monthly installments amount						$ 5,700
Debt interest rate				5.00%		5.00%
Debt maturity date						Aug. 1, 2019
Notes payable, outstanding balance amount		99,000
Accrued interest		$ 3,000
Debt principal amount				$ 99,000		$ 99,000
Convertible Notes Payable [Member]
Conversion price per share				$ 0.36		$ 0.36
Deemed dividend						$ 288,000
Debt converted into shares						1,875,000
Series C Preferred Stock [Member]
Number of additional exchange shares issued		17,264
RMS [Member]
Common stock, par value				33,700		$ 33,700
RMS [Member] | Series C Preferred Stock [Member]
Number of shares issued for acquisition						33,661
Asset Purchase Agreement [Member] | RMS [Member]
Number of shares issued for acquisition		33,661
Number of additional shares issued		6,111
Number of shares issued for acquisition, value		$ 2,000,000
Number of shares converted		1,000
Percentage of voting interest acquired		55.00%
Proceeds from new issuance		$ 5,650,000
Number of additional exchange shares issued		17,264
Cash excluded from purchase transaction		$ 70,000
Convertible debt to a related party		4,300,000
Interest payable		158,000
Accounts payable		224,000
Other current liabilities		$ 285,000
Asset Purchase Agreement [Member] | RMS [Member] | Series C Preferred Stock [Member]
Number of shares issued for acquisition		39,772
Securities Purchase Agreement [Member]
Number of unites issued						15
Conversion price per share				$ 0.40		$ 0.40
Deemed dividend						$ 437,000
Debt principal amount				$ 750,000		$ 750,000
Warrants to purchase common stock				1,875,000		1,875,000
Proceeds from sale of convertible note and equity						$ 750,000
Debt converted into shares						1,875,000
Proceeds from notes						$ 505,424
Proceeds from warrants						$ 244,576
Fair value of notes payable		$ 598,000
Securities Purchase Agreement [Member] | Convertible Notes Payable [Member]
Number of unites issued						1,000,000
Purchase price per unit				$ 50,000		$ 50,000
Debt conversion description						Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company's common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company's common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants are exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants. The notes are secured by all of the assets of the Company.
Common stock, par value				0.001		$ 0.001
Conversion price per share				$ 0.40		$ 0.40
Warrants term				3 years		3 years
Warrant, exercise price				$ 0.75		$ 0.75
Conversion price description						As a result of the price adjustment feature, the conversion price of the convertible notes was adjusted to $0.36 per share. The convertible notes have maturity dates between August and September 2019.

Business Acquisition - Schedule

Business Acquisition - Schedule of Fair Value of Consideration Transferred (Details)	Jan. 08, 2019USD ($)$ / sharesshares
Business Combinations [Abstract]
Common shares issued and outstanding | shares	24,717,271
Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock | shares	2,312,500
Total Common shares | shares	27,029,771
Closing price per share of MDVX Common stock on January 8, 2019 | $ / shares	$ 0.40
Value of common shares	$ 10,811,908
Fair value of outstanding warrants and options	2,220,000
Cash consideration to RMS	(350,000)
Total consideration	$ 12,681,908

Business Acquisition - Schedu_2

Business Acquisition - Schedule of Estimated Fair Values of the Assets Acquired and Liabilities Assumed (Details) - USD ($)	Jun. 30, 2019	Jan. 08, 2019	Dec. 31, 2018
Business Combinations [Abstract]
Cash		$ (302,710)
Accounts receivable, net		145,757
Inventory		131,455
Prepaid expenses		46,153
Property and equipment		30,393
Other		2,751
Intangibles		3,680,000
Goodwill	$ 11,348,724	11,348,724
Total assets acquired		15,082,523
Accounts payable and other accrued liabilities		1,645,399
Interest-bearing liabilities and other		755,216
Net assets acquired		$ 12,681,908

Business Acquisition - Schedu_3

Business Acquisition - Schedule of Interest Bearing and Other Liabilities Assumed (Details)	Jan. 08, 2019USD ($)
Total interest-bearing and other liabilities	$ 755,216
Notes Payable [Member]
Total interest-bearing and other liabilities	99,017
Convertible Notes Payable [Member]
Total interest-bearing and other liabilities	598,119
Dividend Payable [Member]
Total interest-bearing and other liabilities	57,813
Deferred Rent [Member]
Total interest-bearing and other liabilities	$ 267

Business Acquisition - Schedu_4

Business Acquisition - Schedule of Revenue and Net Loss Attributable to Acquisition (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues	$ 2,431,721	$ 2,441,007	$ 3,755,961	$ 5,343,804
Net loss attributable to H-CYTE	(5,297,271)	$ (362,722)	(8,992,087)	$ (1,259,922)
Medovex Corp [Member]
Revenues			35,505
Net loss attributable to H-CYTE	$ (894,585)		$ (1,948,962)

Business Acquisition - Schedu_5

Business Acquisition - Schedule of Pro Forma Financial Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Revenues	$ 2,690,432	$ 5,736,418
Net loss	(1,448,622)	(3,599,608)
Net loss attributable to common shareholders	$ (1,715,679)	$ (3,866,665)
Loss per share- basic and diluted	$ (0.03)	$ (0.07)
RMS [Member]
Revenues	$ 2,441,007	$ 5,343,804
Net loss	(362,722)	(1,259,922)
Net loss attributable to common shareholders	$ (362,722)	$ (1,259,922)
Loss per share- basic and diluted	$ (0.01)	$ (0.01)
Medovex Corp [Member]
Revenues	$ 249,425	$ 392,614
Net loss	(1,085,900)	(2,339,686)
Net loss attributable to common shareholders	$ (1,352,957)	$ (2,606,743)
Loss per share- basic and diluted

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Inventory	$ 129,264
Denervex Device [Member]
Inventory	3,014
Pro-40 Generator [Member]
Inventory	$ 126,250

Right-of-use Asset and Lease _3

Right-of-use Asset and Lease Liability (Details Narrative) - USD ($)	Jun. 30, 2019	Jan. 02, 2019	Dec. 31, 2018
Current lease liabilities	$ 482,632
Long-term lease liabilities	511,930
ROU assets	$ 973,386
Accounting Standards Update (ASU) No. 2016-02 [Member]
Current lease liabilities		$ 475,000
Long-term lease liabilities		713,000
ROU assets		$ 1,167,000

Right-of-use Asset and Lease _4

Right-of-use Asset and Lease Liability - Schedule of Maturities of Lease Liabilities (Details)	Jun. 30, 2019USD ($)
Leases [Abstract]
Remainder of 2019	$ 240,000
2020	454,000
2021	139,000
2022	94,000
2023	68,000
Total	$ 995,000

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 25,000	$ 25,000	$ 52,000	$ 49,000

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Property and equipment	$ 663,061	$ 583,652
Less accumulated depreciation	(403,852)	(316,736)
Property and Equipment, net	259,209	266,916
Furniture and Fixtures [Member]
Property and equipment	$ 214,272	149,285
Furniture and Fixtures [Member] | Minimum [Member]
Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Useful Life	7 years
Computers and Software [Member]
Property and equipment	$ 292,510	278,234
Computers and Software [Member] | Minimum [Member]
Useful Life	3 years
Computers and Software [Member] | Maximum [Member]
Useful Life	7 years
Leasehold Improvements [Member]
Property and equipment	$ 156,279	$ 156,133
Useful Life	15 years

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Beginning balance
Acquisition during the period	3,680,000
Intangible Assets, Ending balance	3,680,000
Amortization	(368,000)
Intangible assets, net	$ 3,312,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Future Amortization of Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2019	$ 368,000
2020	736,000
2021	736,000
2022	736,000
2023	736,000
Total	$ 3,312,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended	6 Months Ended
	Dec. 31, 2018	Mar. 13, 2018	Jun. 30, 2019	Jun. 30, 2019
Short term note received amount	$ 180,000
Michael Yurkowsky [Member]
Officers compensation			$ 5,000	$ 5,000
Mr. Raymond Monteleone [Member]
Officers compensation			5,000	5,000
Michael Yurkowsky and Raymond Monteleone [Member]
Officers compensation			10,000	10,000
Shareholders [Member]
Amount received from related party		$ 528,175
BioCell Capital Line of Credit [Member]
Related party contributions amount	4,300,000
Aforementioned amount	$ 1,856,300
CEO [Member]
Amount received from related party		228,175
Line of credit		$ 1,856,350
Oral Consulting Arrangement [Member] | Mr. Raymond Monteleone [Member]
Advisory service fee				10,000
Audit fees				5,000
Compensation expenses			$ 35,000	$ 70,000

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Apr. 25, 2019	Feb. 28, 2019	Feb. 06, 2019	Jan. 08, 2019	Mar. 31, 2019	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Sep. 28, 2018	Aug. 08, 2018
Number of shares converted			277,778
Common stock, par value							$ 0.001	$ 0.001		$ 0.001
Additional paid-in capital							$ 25,705,975	$ 25,705,975		$ 3,566,339
Accumulated deficit							(13,480,691)	(13,480,691)		$ (9,296,408)
Proceeds from debt								8,656	$ 8,081
Cancellation of debt			$ 100,000
Debt instrument converted value			$ 100,000					125,937
Debt converted into shares			250,000			250,000
Conversion price per share			$ 0.36
Increase in common stock offering limit		$ 8,000,000
Number of common stock issued value							$ 124,477	4,342,423
Number of shares issued for consulting fees					130,085
Shares issued price per share					$ 0.40
Number of shares issued for consulting fees, value					$ 52,034
Total expense in compensation								$ 1,782,413
Stock Option [Member]
Unvested stock options							9,502	9,502
Unrecognized compensation cost							$ 3,900	$ 3,900
Weighted average service period								1 year
2013 Stock Option Incentive Plan [Member]
Compensation expense							3,000	$ 92,000
Convertible Note [Member]
Debt instrument face amount							750,000	750,000
Fair value of notes payable							598,000	$ 598,000
Minimum [Member]
Number of common stock issued value				$ 5,650,000
CEO [Member] | Restricted Stock Award [Member]
Vested percentage								100.00%
Compensation expense							1,693,000	$ 1,782,000
Total expense in compensation								1,690,000
Related to vested amount								1,690,254
Securities Purchase Agreement [Member]
Debt instrument face amount							$ 750,000	$ 750,000
Number of common stock shares sold								15
Debt converted into shares								1,875,000
Conversion price per share							$ 0.40	$ 0.40
Deemed dividend								$ 437,000
Fair value of notes payable				598,000
Securities Purchase Agreement [Member] | Convertible Note [Member]
Debt instrument face amount				$ 50,000
Debt converted into shares				18,000,000
Debt interest rate				12.00%
Debt maturity term				1 year
Conversion price per share				$ 0.40			$ 0.40	$ 0.40
Percentage for common stock outstanding				4.99%
Penalty interest rate				18.00%
Warrant, exercise price				$ 0.75
Warrant term				3 years
Securities Purchase Agreement [Member] | Four Purchasers [Member]
Debt instrument face amount				$ 2,000,000
Proceeds from debt				1,800,000
Cancellation of debt				$ 200,000
Number of units exchanged				40
Number of common stock shares sold				50,000
Proceeds from initially offering				$ 8,000,000
Securities Purchase Agreement [Member] | Four Purchasers [Member] | Convertible Note [Member]
Debt instrument face amount				50,000
Securities Purchase Agreement [Member] | Four Purchasers [Member] | Minimum [Member]
Proceeds from initially offering				1,000,000
Securities Purchase Agreement [Member] | Four Purchasers [Member] | Maximum [Member]
Proceeds from initially offering				$ 6,000,000
Securities Purchase Agreement [Member] | Former Chairman [Member]
Number of units exchanged				4
Debt instrument converted value				$ 200,000
Debt converted into shares				500,000
Securities Purchase Agreement [Member] | Additional Purchasers [Member]
Aggregate amount of capital raised				$ 7,200,000
Employment Agreement [Member] | Mr. William Horne [Member]
Number of common stock issued value	$ 4,225,634
Shares issued price per share	$ 0.40
Vested percentage	100.00%
Aggregate number of shares issued, shares	4,475,634
Compensation expense							$ 1,690,000
Employment Agreement [Member] | CEO [Member] | 2013 Stock Option Incentive Plan [Member]
Vested percentage								100.00%
Number of stock options awarded								250,000
Asset Purchase Agreement [Member] | Convertible Note [Member]
Debt instrument converted value				$ 200,000
Debt converted into shares								500,000
Common Stock [Member]
Number of shares issued for acquisition								24,717,217
Number of shares converted				17,263,889				512,500
Common stock, par value							$ 0.001	$ 0.001
Debt instrument converted value								$ 500
Debt converted into shares								500,000
Number of common stock issued value							$ 500	$ 17,500
Warrant [Member]
Conversion price per share												$ 0.40
Warrant, exercise price											$ 0.75	0.75
Warrant [Member] | Maximum [Member]
Warrant, exercise price											$ 0.75	$ 0.75
Warrant [Member] | Securities Purchase Agreement [Member]
Conversion price per share				$ 0.36
Deemed dividend				$ 117,000
Series C Preferred Stock [Member]
Number of additional exchange shares issued				17,264
Series B Convertible Preferred Stock [Member]
Number of shares converted								636,480
Preferred stock, par value							$ 0.001	$ 0.001		$ 0.001
Series B Preferred Stock [Member]
Number of shares converted								2,250
Number of common stock shares sold								9,250
Beneficial conversion feature				$ 33,000
Preferred stock, par value							0.001	$ 0.001
Series B Preferred Stock [Member] | Common Stock [Member]
Number of shares converted								562,500
RMS [Member]
Common stock, par value							$ 33,700	$ 33,700
Additional paid-in capital							$ 3,566,000	$ 3,566,000
Accumulated deficit							$ 9,296,000	$ 9,296,000
RMS [Member] | Asset Purchase Agreement [Member]
Number of shares issued for acquisition				33,661
Number of shares converted				1,000
Number of common stock issued value				$ 5,650,000
Number of additional exchange shares issued				17,264
RMS [Member] | Common Stock [Member]
Number of shares converted								33,661,000
RMS [Member] | Series C Preferred Stock [Member]
Number of shares issued for acquisition								33,661
RMS [Member] | Series C Preferred Stock [Member] | Asset Purchase Agreement [Member]
Number of shares issued for acquisition				39,772

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Option Activity (Details) - $ / shares	Jan. 08, 2019	Jun. 30, 2019
Equity [Abstract]
Number of Shares Options Outstanding Beginning Balance
Number of Shares Options, Assumed with the RMS merger transaction	557,282
Number of Options Granted		250,000
Number of Options Cancelled		(289,774)
Number of Shares Options Outstanding Ending Balance		517,508
Number of Shares Options Exercisable		508,007
Weighted Average Exercise Price Outstanding Beginning Balance
Weighted Average Exercise Price, Assumed with the RMS merger transaction	$ 2.78
Weighted Average Exercise Price Granted		$ 0.40
Weighted Average Exercise Price Cancelled		2.59
Weighted Average Exercise Price Outstanding Ending Balance		1.81
Weighted Average Exercise Price Exercisable		$ 1.81
Weighted Average Remaining Term (years) Outstanding, Beginning	0 years
Weighted Average Remaining Term (years) Assumed with the RMS merger transaction	6 years 11 months 26 days
Weighted Average Remaining Term (years) Outstanding, Granted		9 years 6 months 10 days
Weighted Average Remaining Term (years) Outstanding, Ending		7 years 10 months 14 days
Weighted Average Remaining Term (years) Exercisable		7 years 10 months 14 days

Commitments & Contingencies (De

Commitments & Contingencies (Details Narrative)	1 Months Ended	3 Months Ended			6 Months Ended
	Jan. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2019EUR (€)	Jun. 30, 2018USD ($)
Payments for consulting services		$ 492,145		$ 644,236	$ 988,964		$ 1,475,373
Sub-Lease Agreement [Member] | July 1, 2019 to December 31, 2020 [Member]
Minimum rental amount					2,000
Consulting Agreement [Member]
Consulting fees					13,333
Payments for consulting services		0			$ 39,999
Consulting Agreement [Member] | LilyCon Investments, LLC [Member]
Consulting fees			$ 12,500
Signing bonus			$ 15,000
Agreement, description					The agreement also provides LilyCon Investments with $35,000 in stock (calculated using an annual Variable Weighted Average Price from February 2019 through January 2020) to be granted upon completion of the consulting services first year. Either party may terminate this agreement with without cause upon (30) days written notice.	The agreement also provides LilyCon Investments with $35,000 in stock (calculated using an annual Variable Weighted Average Price from February 2019 through January 2020) to be granted upon completion of the consulting services first year. Either party may terminate this agreement with without cause upon (30) days written notice.
Compensation expenses		37,500			$ 77,500
Oral Consulting Arrangement [Member] | Mr. Raymond Monteleone [Member]
Compensation expenses		35,000			70,000
Advisory service fee					10,000
Audit fees					5,000
Oral Consulting Arrangement [Member] | St. Louis Family Office, LLC [Member]
Consulting fees		44,000			71,000
Advisory service fee	$ 10,000
Consulting Arrangement [Member] | Strategos Group [Member]
Consulting services		26,000			26,000
Distribution Center and Logistic Services Agreement [Member]
Audit fees					5,040
Total incurred expense		22,500			45,000
Distribution Center and Logistic Services Agreement [Member] | Minimum [Member]
Audit fees					2,300
Distribution Center and Logistic Services Agreement [Member] | Maximum [Member]
Audit fees					$ 8,300
Distribution Center and Logistic Services Agreement [Member] | EURO [Member]
Audit fees | €						€ 4,500
Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Minimum [Member]
Audit fees | €						1,900
Distribution Center and Logistic Services Agreement [Member] | EURO [Member] | Maximum [Member]
Audit fees | €						€ 6,900
Patent Assignment and Contribution Agreement [Member]
Agreement, description					This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products. The royalty period expires on September 6, 2030.	This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products. The royalty period expires on September 6, 2030.
Contribution and Royalty agreement [Member]
Royalty expense		0			$ 1,100
Management Services Agreements [Member]
Total guaranteed payments		$ 34,000		$ 20,000	$ 56,000		$ 59,000

Short Term Liabilities (Details

Short Term Liabilities (Details Narrative) - USD ($)	Feb. 06, 2019	Jun. 30, 2019	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Common stock, par value		$ 0.001		$ 0.001		$ 0.001		$ 0.001
Market value of common stock	$ 0.36
Debt description	The Company is in the process of negotiating a 30-day extension of the maturity dates. If the Company is unable to extend the maturity date, the notes will go into default until additional funding is received to payoff these notes and the mandatory default amounts will have to be paid. The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes.
Proceeds from issuance of note payable							$ 1,967,724
Proceeds from warrants						2,565,638
Number of shares issued on conversion	250,000		250,000
Proceeds from debt	$ 100,000					$ 200,000
Debt conversion convertible outstanding	$ 750,000
Conversion of stock shares converted	277,778
RMS [Member]
Common stock, par value		$ 33,700		$ 33,700		$ 33,700
Convertible Debenture [Member] | RMS [Member]
Interest expense					$ 42,000		71,000
Promissory Note [Member]
Interest expense				$ 1,300		$ 2,100
Monthly installment amount						$ 5,700
Debt instrument interest rate		5.00%		5.00%		5.00%
Debt principal amount		$ 99,000		$ 99,000		$ 99,000
Scheduled payment amount		$ 5,700
Debt instrument maturity date						Aug. 1, 2019
Convertible Notes Payable [Member]
Market value of common stock		$ 0.36		$ 0.36		$ 0.36
Number of shares issued on conversion						1,875,000
Deemed dividend						$ 288,000
Finance Agreement [Member]
Insurance premium finance payments due		$ 18,000		$ 18,000		18,000
Insurance premium finance payments, remaining balance		$ 95,000		95,000		95,000		$ 31,000
Interest expense				$ 2,000	$ 0	$ 2,300	$ 0
Finance Agreement [Member] | Minimum [Member]
Insurance premium finance annual percentage		7.00%		7.00%		7.00%
Finance Agreement [Member] | Maximum [Member]
Insurance premium finance annual percentage		12.80%		12.80%		12.80%
Securities Purchase Agreement [Member]
Debt principal amount		$ 750,000		$ 750,000		$ 750,000
Market value of common stock		$ 0.40		$ 0.40		$ 0.40
Proceeds from issuance of note payable						$ 505,424
Proceeds from warrants						$ 244,576
Number of shares issued on conversion						1,875,000
Deemed dividend						$ 437,000
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Interest expense				$ 63,600		127,900
Number of common stock shares sold, value						$ 750,000
Sale of stock price per share		50,000		$ 50,000		$ 50,000
Conversion of common stock, percentage						12.00%
Common stock, par value		0.001		0.001		$ 0.001
Market value of common stock		$ 0.40		$ 0.40		$ 0.40
Debt description						Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company's common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company's common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Warrants were initially exercisable at a price equal to the lesser of $0.75 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of the debt and/or equity securities completed by the Company following the issuance of warrants.
Warrant term		3 years		3 years		3 years
Warrant, exercise price		$ 0.75		$ 0.75		$ 0.75
Unpaid accrued interest related debt				$ 21,500		$ 41,200
Securities Purchase Agreement [Member] | Convertible Notes Payable [Member]
Common stock, par value		0.001		$ 0.001		$ 0.001
Market value of common stock		$ 0.40		$ 0.40		$ 0.40
Warrant term		3 years		3 years		3 years
Warrant, exercise price		$ 0.75		$ 0.75		$ 0.75

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Equity [Abstract]
Number of Shares, Warrants Outstanding Beginning | shares	12,108,743
Number of Shares, Warrants Issued | shares	18,000,000
Number of Shares, Warrants Outstanding and Exercisable Ending | shares	30,108,743
Weighted Average Exercise Price Outstanding | $ / shares	$ 1.38
Weighted Average Exercise Price Warrants Issued | $ / shares	0.75
Weighted Average Exercise Price Outstanding | $ / shares	$ 0.95	[1],[2]
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	2 years 7 months 6 days
Weighted Average Remaining Contractual Life Warrants Outstanding, Issued	2 years 7 months 2 days
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	2 years 4 months 17 days
[1]	Warrants issued with the August 8, 2018 and September 28, 2018 convertible notes had an initial exercise price of $0.75 and contain a contingent feature which would adjust the exercise price of the warrants in the event the Company issued any shares of common stock or common stock equivalents in a private placement of equity or debt securities to 90% of the issuance price if it is less than $0.75.
[2]	Warrants issued with the May 2018 private placement and debt conversion had an initial exercise price of $0.75 and contain a contingent feature which would adjust the exercise price of the warrant in the event the Company issues any shares of common stock or common stock equivalents in a private placement of equity or debt securities at a price less than $0.75 per share. On August 8, 2018, the Company completed the issuance of convertible debt at an initial conversion price of $0.40. Accordingly, the exercise price on these warrants was adjusted downward to $0.40.

Common Stock Warrants - Summa_2

Common Stock Warrants - Summary of Warrant Activity (Details) (Parenthetical) - $ / shares	Sep. 28, 2018	Aug. 08, 2018	Feb. 06, 2019	May 31, 2018
Conversion price per share			$ 0.36
Warrant [Member]
Warrant initial exercise price	$ 0.75	$ 0.75
Conversion price per share		0.40
Warrant adjusted downward per share		$ 0.40
Warrant equity percentage	90.00%	90.00%
Maximum [Member] | Warrant [Member]
Warrant initial exercise price	$ 0.75	$ 0.75
May 2018 Private Placement [Member]
Warrant initial exercise price				$ 0.75
May 2018 Private Placement [Member] | Maximum [Member]
Warrant initial exercise price				$ 0.75

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Assumptions for Warrants (Details)	6 Months Ended
	Jun. 30, 2019$ / shares
Private Placement 1/08/2019 [Member]
H-CYTE Stock Price	$ 0.40
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.24
Life of Warrant	3 years
Private Placement 1/08/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.57
Private Placement 1/08/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	115.08
Private Placement 1/18/2019 [Member]
H-CYTE Stock Price	$ 0.40
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.23
Life of Warrant	3 years
Private Placement 1/18/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.60
Private Placement 1/18/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	114.07
Private Placement 1/25/2019 [Member]
H-CYTE Stock Price	$ 0.59
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.38
Life of Warrant	3 years
Private Placement 1/25/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.43
Private Placement 1/25/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.72
Private Placement 1/31/2019 [Member]
H-CYTE Stock Price	$ 0.54
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.34
Life of Warrant	3 years
Private Placement 1/31/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.43
Private Placement 1/31/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.47
Private Placement 2/7/2019 [Member]
H-CYTE Stock Price	$ 0.57
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.36
Life of Warrant	3 years
Private Placement 2/7/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.46
Private Placement 2/7/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.23
Private Placement 2/22/2019 [Member]
H-CYTE Stock Price	$ 0.49
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.30
Life of Warrant	3 years
Private Placement 2/22/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.46
Private Placement 2/22/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.34
Private Placement 3/1/2019 [Member]
H-CYTE Stock Price	$ 0.52
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.33
Life of Warrant	3 years
Private Placement 3/1/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.54
Private Placement 3/1/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.42
Private Placement 3/8/2019 [Member]
H-CYTE Stock Price	$ 0.59
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.38
Life of Warrant	3 years
Private Placement 3/8/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.43
Private Placement 3/8/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.53
Private Placement 3/11/2019 [Member]
H-CYTE Stock Price	$ 0.61
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.40
Life of Warrant	3 years
Private Placement 3/11/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.45
Private Placement 3/11/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.62
Private Placement 3/26/2019 [Member]
H-CYTE Stock Price	$ 0.51
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.32
Life of Warrant	3 years
Private Placement 3/26/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.18
Private Placement 3/26/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	113.12
Private Placement 3/28/2019 [Member]
H-CYTE Stock Price	$ 0.51
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.31
Life of Warrant	3 years
Private Placement 3/28/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.18
Private Placement 3/28/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	112.79
Private Placement 3/29/2019 [Member]
H-CYTE Stock Price	$ 0.51
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.31
Life of Warrant	3 years
Private Placement 3/29/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.21
Private Placement 3/29/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	112.79
Private Placement 4/4/2019 [Member]
H-CYTE Stock Price	$ 0.48
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.29
Life of Warrant	3 years
Private Placement 4/4/2019 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	2.29
Private Placement 4/4/2019 [Member] | Measurement Input, Price Volatility [Member]
Warrant Input, Percentage	112.77

Liquidity, Going Concern and _2

Liquidity, Going Concern and Management's Plans (Details Narrative) - USD ($)	Jul. 29, 2019	Jun. 07, 2019	Feb. 06, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jul. 26, 2019	Jul. 25, 2019	Mar. 31, 2019	Dec. 31, 2018
Net loss				$ 5,297,271	$ 362,722	$ 8,992,087	$ 1,259,922
Additional cash raised						7,100,000
Cash raised through debt conversion			$ 100,000			200,000
Cash				300,068		300,068					$ 69,628
Debt description			The Company is in the process of negotiating a 30-day extension of the maturity dates. If the Company is unable to extend the maturity date, the notes will go into default until additional funding is received to payoff these notes and the mandatory default amounts will have to be paid. The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes.
Share price per share										$ 0.40
New Private Placements [Member]
Private placement offering amount		$ 8,500,000				100,000
Share price per share		$ 0.50
Warrant term		3 years
Warrant description		The Board of Directors approved a new private placements securities offering up to $8,500,000 of Common Stock at a price of $0.50 per share, and a three-year warrant to purchase such number of shares of Common Stock equal to fifty percent (50%) of the number of shares of Common Stock issuable as part of this Agreement (the "Warrants"), at an exercise price of $1.00 per share.
Warrant, exercise price		$ 1
Convertible Promissory Notes [Member]
Debt principal amount				650,000		$ 650,000
Debt maturity date description						Between August 8, 2019 and September 28, 2019.
Debt description						The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes.
Promissory Notes [Member]
Debt principal amount				$ 99,000		$ 99,000
Debt maturity date description						The notes have a maturity date of August 1, 2019
Subsequent Event [Member]
Debt description	The board of directors (the "Board") of the Company appointed Dr. Andre Terzic to the Board. Dr. Andre Terzic, 57, has served as a director at the Center for Regenerative Medicine of Mayo Clinic in Rochester, Minnesota for the last five years
Subsequent Event [Member] | Two Promissory Notes [Member]
Debt bear interest rate								5.50%	5.50%
Subsequent Event [Member] | Two Promissory Notes [Member] | Horne Management, LLC[Member]
Debt principal amount								$ 900,000	$ 900,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jul. 29, 2019	Feb. 06, 2019	Jun. 30, 2019	Jul. 26, 2019	Jul. 25, 2019
Debt description		The Company is in the process of negotiating a 30-day extension of the maturity dates. If the Company is unable to extend the maturity date, the notes will go into default until additional funding is received to payoff these notes and the mandatory default amounts will have to be paid. The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes.
Convertible Promissory Notes [Member]
Principal amount of promissory note			$ 650,000
Debt description			The mandatory default amount means the sum of (a) 120% of the outstanding principal amount of this Note, plus 100% of accrued and unpaid interest hereon, and (b) all other amounts, costs, expenses and liquidated damages due in respect of these notes.
Debt maturity date description			Between August 8, 2019 and September 28, 2019.
Promissory Notes [Member]
Principal amount of promissory note			$ 99,000
Debt maturity date description			The notes have a maturity date of August 1, 2019
Subsequent Event [Member]
Debt description	The board of directors (the "Board") of the Company appointed Dr. Andre Terzic to the Board. Dr. Andre Terzic, 57, has served as a director at the Center for Regenerative Medicine of Mayo Clinic in Rochester, Minnesota for the last five years
Subsequent Event [Member] | Two Promissory Notes [Member]
Debt bear interest rate				5.50%	5.50%
Subsequent Event [Member] | Two Promissory Notes [Member] | Horne Management, LLC[Member]
Principal amount of promissory note				$ 900,000	$ 900,000